

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

AMAZING NEPHROLOGY

FINAL
PROGRAMME



CONGRESS INFORMATION

Please click on the links below to see the content.

> **GENERAL INFORMATION**

> **ERA COUNCIL MEMBERS**

> **CONGRESS SCIENTIFIC COMMITTEE**

> **BEST ABSTRACTS**

- ★ Ten best abstracts
- 🌐 Eight best abstracts presented by young authors
- 💖 Best abstracts presented by young authors

WELCOME ADDRESS



Piergiorgio Messa,
Local Congress President



Christoph Wanner
ERA President

Dear colleagues and friends,

As many of you may remember, the 2020 Congress was supposed to be held in Milan (Italy), but due to the difficulties and the lockdown caused by Covid 19, we were forced to hold the Congress virtually.

Now, after three years, we are very happy to be able to welcome all of you face-to-face in Milan.

The ERA Annual Congress aims at sharing knowledge to further improve the prevention and quality of life of patients by providing an update on the clinical assessment and treatment of kidney diseases.

This year's theme, **Research, Education, Governance and Equality**, was chosen by **Francesca Mallamaci**, Chair of the Scientific Committee.

Research: is the basis of our lives, new therapies and the confirmation of old ones will not only support the cure of kidney disease but will also improve the quality of life of kidney patients.

Education: we are looking into the future. Healthcare professionals want to be prepared to provide high-quality, evidence-based care, adapt to new technologies and contribute to ongoing advances in medical practice and research.

Governance and equity are two interrelated concepts that play a crucial role in shaping societies and ensuring fair and equitable systems. Health equity focuses on ensuring that everyone has equal access to health services and that health outcomes are not determined by factors such as gender, race, income, or social status. It includes addressing health disparities and promoting health equity.

As in the past, the first day of the Milan 2023 Congress will feature educational sessions organised by the **CME** (Continuing Medical Education) **Committee**, chaired by **Marianne Verhaar**, as well as hands-on courses, overseen by **Kate Stevens**. This year, the CME Committee has planned **four hands-on courses** and **eight CME courses** lasting from half a day to a full day.

The Scientific Committee, chaired by **Francesca Mallamaci**, worked very hard to provide the best programme by selecting international experts and well-known Kols (Key opinion Leaders). She was in particular supported by **Ronald Gansevoort**, who chaired the paper selection committee, and by the Congress President, **Piergiorgio Messa**, and the Honorary Congress President, **Lucretia Gassmann**.

A large number of high-quality abstracts, received from **86 countries**, confirms the strong interest in our Congress, furthermore, we received a record number of Late Breaking Clinical Trial (LBCT) abstracts that resulted in presenting **two sessions** of LBCT, for a total of eight large randomised clinical trials, clearly indicating that clinical research in kidney disease is growing.

A novelty introduced from the 60th ERA Congress is the simplification and harmonization of the number and content of Congress tracks and abstract categories, from 18 main categories and 38 subcategories to 7 main categories (the same as the Congress themes), we will also have two **new sessions** on **clinical practice**.

The programme will also include a **new session** to replace the standard Poster session: the **Focused Orals**. All accepted abstracts will be discussed orally in dedicated rooms located within the exhibition area. No more paper posters for a more sustainable congress and more space for discussion.

An additional and new educational opportunity that you can take advantage of are the **Creative Labs**, a frontal lesson that will give you in-depth knowledge into specific practical topics. Experts will give you important and up-to-date information on the **checklist for setting up a clinical trial, ethics in publishing, how to ruin your presentation and balancing parenthood and career**.

Finally, the programme will be completed with several interesting industry symposia.

The Milan 2023 Congress will also be an opportunity to celebrate how much history and dedication have shaped our Association in its 60-year commitment to reducing the burden of chronic kidney disease. It's great to be celebrating such a milestone and we hope that the Congress will be a successful and enlightening event for all those who attend.

We look forward to welcoming you to the 60th ERA Congress!

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023	5
<hr/>	
FRIDAY - JUNE 16, 2023	11
<hr/>	
SATURDAY - JUNE 17, 2023	26
<hr/>	
SUNDAY - JUNE 18, 2023	42

MODERATED ORALS & FOCUSED ORALS

FRIDAY - JUNE 16, 2023	25
-------------------------------	-----------

INDUSTRY SPONSORED SYMPOSIA

FRIDAY - JUNE 16, 2023	46
-------------------------------	-----------

SATURDAY - JUNE 17, 2023	56
---------------------------------	-----------

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

**15
THU**

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

CME & HANDS-ON COURSES

CONGRESS OPENING	6
PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES	6
HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD	6
CKD AND BONE MINERAL DISORDERS IN CKD	6
KIDNEY TRANSPLANTATION	7
HAND-ON COURSE ON RENAL BIOPSY (MORNING COURSE)	7
HAND-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA (FULL DAY)	7
HAND-ON COURSE ON CATHETER PLACEMENT (MORNING COURSE)	7
HAND-ON COURSE ON POCUS (FULL DAY COURSE)	8
HAEMO- AND PERITONEAL DIALYSIS	8
BASICS OF GENETICS FOR NEPHROLOGISTS	8
ACUTE KIDNEY INJURY	8
ELECTROLYTES AND UROLITHIASIS	9
HAND-ON COURSE ON RENAL BIOPSY (AFTERNOON COURSE)	9
HAND-ON COURSE ON CATHETER PLACEMENT (AFTERNOON COURSE)	9
WELCOME CEREMONY + WELCOME LECTURE	10

HALL GOLD (PLENARY) 08:00 - 08:30 (CEST)

CONGRESS OPENING**Welcome words**

Piergiorgio Messa (Local Congress President), Italy

Abstract submission

Ronald Gansevoort (Chair of Paper Selection Committee), The Netherlands

Most important sessions

Francesca Mallamaci (Chair of Scientific Committee), Italy

Congress official opening

Christoph Wanner (ERA President), Germany

HALL AUDITORIUM 08:45-12:20 (CEST)

**CME 1
PRIMARY & SECONDARY GN,
VASCULITIS AND AUTOIMMUNE
DISEASES**

Chairs: Annette Bruchfeld, Andreas Kronbichler

1. Predicting kidney function recovery in ANCA-associated vasculitis and anti-GBM disease
Alan Salama, United Kingdom
2. Deposition diseases and the kidney – diagnostic steps beyond the kidney and therapeutic aspects
Helen Lachmann, United Kingdom
3. B-cell depletion in podocytopathies and membranous nephropathy
Philipp Gauckler, Austria
4. Pathology in lupus nephritis – 2023 revised
Maddalena Maria Bolognesi, Italy
5. ANCA-associated vasculitis in the elderly – diagnostic and therapeutic aspects.
Maria Weiner, Sweden

HALL SPACE 1 & 2 08:45-12:20 (CEST)

**CME 2
HYPERTENSION, DIABETES,
CARDIOVASCULAR DISEASES IN CKD**

Chairs: Beatriz Fernandez Fernandez, Pantelis Sarafidis, Amaryllis Van Craenenbroeck

**PART 1:
REVISITING THE ROLE OF NATRIURESIS/
DIURESIS IN CKD**

1. Mechanisms on diuretic resistance in CKD
Amaryllis Van Craenenbroeck, The Netherlands
2. Renal mechanisms involved in the benefits offered by SGLT2 inhibitors in HF
Maria Eleni Alexandrou, Greece
3. BP CONTROL with diuretic treatments. Old drugs back into business
Beatriz Fernández-Fernández, Spain
4. Is there a still a role for diuretics in hemodialysis and peritoneal dialysis?
Manfred Hecking, Austria
5. Round table discussion

**PART 2:
NOVEL DIAGNOSTIC ASPECTS IN CKD**

1. Bold MRI to assess tubulointerstitial damage in CKD
Menno Pruijm, Switzerland
2. Blood pressure control and cardiovascular risk factors in the COVID 19 era
Andrzej Januszewicz, Poland
3. Discussion

**PART 3:
NOVEL THERAPEUTIC ASPECTS IN CKD**

4. Cardiovascular morbidity and mortality reduction in CKD. Do SGLT2 inhibitors and finerenone finally change the landscape?
Charles Ferro, United Kingdom
5. The HIF system and the cardiovascular system: benefits and weaknesses of the novel HIF stabilizers for anemia treatment.
Lucia del Vecchio, Italy

HALL SPACE 3 & 4 08:45-12:20 (CEST)

**CME 3
CKD AND BONE MINERAL
DISORDERS IN CKD**

Chairs: Hanne Joergensen, Jelmer Humalda, Sandro Mazzaferro

1. Introduction: Treatment targets in CKD-MBD
Hanne Jørgensen, Denmark
2. Pathophysiology of hyperparathyroidism in bone and vessels
Lucile Figueres, France
3. Response to PTH in target organs
Pieter Evenepoel, Belgium
4. PTH; standardizing assays and killing myths
Etienne Cavalier, Belgium
5. Quiz: How would you handle this case in clinical practice?
Jelmer Humalda, The Netherlands
6. Expert panel: How would you handle this case in clinical practice?
Lucile Figueres, France
Pieter Evenepoel, Belgium
Matthias Haarhaus, Sweden
7. Calcium balance – a forgotten target in CKD?
Rukshana Shroff, United Kingdom
8. Bone and vascular biomarkers as treatment targets of CKD-MBD
Maria Fusaro, Italy
9. Future aspects in CKD-MBD treatment targets
Sandro Mazzaferro, Italy

HALL BROWN 3

08:45-12:20 (CEST)

**CME 5
KIDNEY TRANSPLANTATION****Chairs:** *Marta Crespo, Christophe Mariat, Jasper Callemeyn*

1. Alloreognition and the spectrum of kidney transplant rejection
Jasper Callemeyn, Belgium
2. PRO/CON topic: Do I treat subclinical ABMR? In response to a clinical case (Pro Speaker) *O. Thaumat, France* (Con Speaker) *Georg Böhmig, Austria*
3. Xenotransplantation: the ultimate solution for end-stage renal disease?
Manuel Pascual, France
4. Therapeutic strategies to improve allograft longevity: new drugs for diabetes
Isabel Perez-Flores, Spain
5. Safety of immune checkpoint inhibitor therapy after kidney transplantation
Ben Sprangers, Belgium

HALL BROWN 1 & 2

08:45-12:20 (CEST)

HAND-ON COURSE ON RENAL BIOPSY (MORNING COURSE)

This courses will be done using MAX-CORE biopsy systems; please considered that similar products from other companies are available on the market

Chairs: *Emily McQuarrie, Loreto Gesualdo*

1. Introduction
Emily McQuarrie, United Kingdom
2. Indications and epidemiology of native kidney biopsy
Colin Geddes, United Kingdom
3. Practical aspect of Biopsy
4. Practical pathology for Biopsy (Processing of the samples and tests)
Candice Roufosse, United Kingdom
5. Complications of Kidney Biopsy
Loreto Gesualdo, Italy
6. US demonstration
Antonio Granata, Italy
7. Biopsy demonstration and Practice
Emily McQuarrie, United Kingdom
Loreto Gesualdo, Italy
Stefanie Heidenreich, Germany
Adele Mitrotti, Italy
Michele Rossini, Italy
Mauro Forcella, Italy
Antonio Granata, Italy
Eleni Ioannou, Greece
Keith Gillis, United Kingdom

HALL AMBER 1 & 2

08:45-15:00 (CEST)

HAND-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA (FULL DAY)**Chairs:** *Tamara Jemcov, Jose Ibeas*

1. Introduction
Jose Ibeas, Spain
2. How to examine a vascular access
Jernej Pajek, Slovenia
3. Non maturing AVF
Tamara Jemcov, Serbia
4. Venous outflow Stenosis
Nicola Pirozzi, Italy
5. The aneurysmal AVF
Karen Stevenson, United Kingdom
6. Discussion
7. Graft thrombosis
Karen Stevenson, United Kingdom
8. Recirculation
Matteo Tozzi, Italy
9. US demonstration
Jose Ibeas, Spain
10. US practice
Jose Ibeas, Spain
Jennifer Hanko, United Kingdom
Tamara Jemcov, Serbia
Mariusz Kuzstal, Poland
Jernej Pajek, Slovenia
Nicola Pirozzi, Italy
Karen Stevenson, United Kingdom
Matteo Tozzi, Italy
11. Concluding Remarks
Jose Ibeas, Spain

HALL AMBER 3 & 4

08:45-12:20 (CEST)

HAND-ON COURSE ON CATHETER PLACEMENT (MORNING COURSE)

This course will be done using Palindrome™ catheter family; please considered that similar products from other companies are available on the market

Chairs: *Kate Stevens, Maurizio Gallieni*

1. Introduction
Kate Stevens, United Kingdom
2. Minimising catheter associated infection
Maria Guedes Marques, Portugal
3. Kinking and Tip position
Carlo Lomonte, Italy
4. Assessment and management of central vein stenosis and atrial thrombus
Sokratis Stoumpos, United Kingdom
5. Discussion
6. Demonstration Tunnelled Line Insertion & Non tunnelled Line insertion
Maurizio Gallieni, Italy
7. Practice
Kate Stevens, United Kingdom
Maurizio Gallieni, Italy
Maria Guedes Marques, Portugal
Jennifer Lees, United Kingdom
Carlo Lomonte, Italy
Sokratis Stoumpos, United Kingdom
Peter Thomson, United Kingdom
Paolo Ria, Italy
Paolo Luca Maria, Italy
Ioannis Giannikouri, Greece

The 2023 Hands-on courses will be done using the following ultrasound devices: SonoEye P2, Resona I9 and M9, CERBERO 4.0, Ultrasound System 3300 and CX50. Please consider that similar products from other companies are available on the market.

HALL AMBER 5

8:45-16:15 (CEST)

**HAND-ON COURSE ON POCUS
(FULL DAY COURSE)****Chairs:** Hugo Diniz & Gregorio Gonzalez

1. Introduction
Hugo Diniz, Portugal
2. POCUS in Nephrology: what's the point?
Hugo Diniz, Portugal
3. Discussion
4. Principles of US and Knobology
José Mariz, Portugal
5. POCUS of the kidney and urinary tract
Sinead Stoneman, Ireland
6. Discussion
7. Lung and cardiac US for the nephrologist
Fredzzia Amada Graterol Torres, Spain
8. POCUS for volemia assessment: wet or dry?
Gregorio Gonzalez, Spain
9. Discussion
Clinical case discussion
Filipa Ferreira, Portugal
Raquel Barba, Spain
10. POCUS practice
Hugo Diniz, Portugal
Sinead Stoneman, Ireland
Raquel Barba, Spain
Filipa Ferreira, Portugal
Fredzzia Amada Graterol Torres, Spain
Carlos Narváez Mejía, Spain
José Mariz, Portugal
James Gleeson, Ireland
Gregorio A. Romero-González, Spain
Marco Antonio Vaca Gallardo Spain
11. Concluding remarks
Hugo Diniz, Portugal

HALL AUDITORIUM

13:00-16:30 (CEST)

**CME 4
HAEMO- AND PERITONEAL DIALYSIS****Chairs:** Rukshana Shroff, Mehmet Kanbay, Karlien Francois**SESSION I – Volume management****Chairs:** Carlo Basile and Rukshana Shroff

1. Hemodynamic instability in patients on dialysis: causes and management
Mehmet Kanbay, Turkey
2. Dialysis vs medications for heart failure? - a cardiologist's perspective
Frederik Verbrugge, Belgium
3. Optimizing dialysis for patients with heart failure
Andrew Davenport, United Kingdom
4. Round table discussion

SESSION II – Best practice in dialysis**Chairs:** Sandip Mitra and Karlien Francois

1. Transition between kidney replacement therapies
Christian Combe, France
2. Care for elderly dialysis patients
Marjolijn van Buren, The Netherlands
3. Point of care ultrasound in nephrology
Joaquin Escola, Spain
4. Round table discussion

SESSION III – Dialysis Access in 2023**Chairs:** Mehmet Kanbay and Gaetano Alfano

1. The complex relationship among arteriovenous access, heart, and circulation.
Carlo Basile, Italy
2. Best practice in AVF cannulation
Giacomo Forneris, Italy
3. Improving PD access - learning from registry data
Martin Wilkie, United Kingdom
4. Round table discussion

HALL SPACE 1 & 2

13:00-16:30 (CEST)

**CME 8
BASICS OF GENETICS FOR
NEPHROLOGISTS****Chairs:** Emilie Cornec-Le Gall, Roser Torra, Lucille Figueres

1. Test your knowledge in basics of genetics: Let's start by a quizz session
Elisabet Ars, Spain
2. Actionable genes in kidney diseases: definition and practical examples
Jan Halbritter, Germany
3. Pre-symptomatic diagnosis of inherited kidney diseases in at-risk children: When? When not? By whom? How? Why?
Djalila Meckali, Belgium
4. Genetics for the transplant nephrologist
Peter Conlon, Ireland
5. Genetic-based therapeutic approaches in kidney diseases: are we there yet?
John Sayer, Belgium
6. Clinical cases for the adult nephrologist: another quizz to end the session
John Sayer, United Kingdom
Emilie Cornec Le Gal, France

HALL SPACE 3 & 4

13:00-16:30 (CEST)

**CME 6
ACUTE KIDNEY INJURY****Chairs:** Valerie Luycks, Vincenzo Cantaluppi, Turgay Saritas

1. Clinical implications of basic science discoveries in AKI
Turgay Saritas, Germany
2. Sepsis-associated AKI and targets for extracorporeal blood purification therapies
Marco Fiorentino, Italy
3. How to do peritoneal dialysis for AKI?
Daniela Ponce, Brazil
4. How to prescribe and troubleshoot CKRT in critically ill patients?
John Prowle, United Kingdom
5. AKI management: challenging cases and panel discussion
All speakers and audience

HALL BROWN 3

13:00-16:30 (CEST)

**CME 7
ELECTROLYTES AND UROLITHIASIS****Chairs:** *Olivier Bonny, Jean-Philippe Bertocchio, Ewout Hoorn*

1. Tubulopathies: should we sequence everyone?
Franz Schafer, Germany
2. Withholding medications or restricting dietary potassium to prevent hyperkalemia; Still a good idea?
Juan-Jesus Carrero, Sweden
3. Uric acid nephropathy: does it exist?
Stefanie Steiger, Germany
4. X-linked hypophosphatemia: who should we treat and for how long?
Justine Bacchetta, France
5. Alkali therapy for kidney protection in kidney transplant recipients with metabolic acidosis.
Nilufar Mohebbim Switzerland

HALL BROWN 1 & 2

13:00-16:30 (CEST)

HAND-ON COURSE ON RENAL BIOPSY (AFTERNOON COURSE)

This course will be done using MAX-CORE biopsy systems; please consider that similar products from other companies are available on the market

Chairs: *Emily McQuarrie, Loreto Gesualdo*

1. Introduction
Emily McQuarrie, United Kingdom
2. Indications and epidemiology of native kidney biopsy
Colin Geddes, United Kingdom
3. Practical aspect of Biopsy
4. Practical pathology for Biopsy (Processing of the samples and tests)
Candice Roufosse, United Kingdom
5. Complications of Kidney Biopsy
Loreto Gesualdo, Italy
6. US demonstration
Mario Meola, Italy
7. Biopsy demonstration and Practice
Emily McQuarrie, United Kingdom
Colin C. Geddes, United Kingdom
Loreto Gesualdo, Italy
Stefanie Heidenreich, Germany
Adele Mitrotti, Italy
Michele Rossini, Italy
Mauro Forcella, Italy
Antonio Granata, Italy

HALL AMBER 3 & 4

13:00-16:30 (CEST)

HAND-ON COURSE ON CATHETER PLACEMENT (AFTERNOON COURSE)

This course will be done using Palindrome™ catheter family; please consider that similar products from other companies are available on the market

Chairs: *Kate Stevens, Maurizio Gallieni*

1. Introduction
Kate Stevens, United Kingdom
2. Minimising catheter associated infection
Maria Guedes Marques, Portugal
3. Kinking and Tip position
Carlo Lomonte, Italy
4. Assessment and management of central vein stenosis and atrial thrombus
Sokratis Stoumpos, United Kingdom
5. Discussion
6. Demonstration Tunnelled Line Insertion & Non tunnelled Line insertion
Maurizio Gallieni, Italy
7. Practice
Kate Stevens, United Kingdom
Maurizio Gallieni, Italy
Maria Guedes Marques, Portugal
Jennifer Lees, United Kingdom
Carlo Lomonte, Italy
Sokratis Stoumpos, United Kingdom
Peter Thomson, United Kingdom
Paolo Ria, Italy
Paolo Luca Maria, Italy
Ioannis Giannikouri, Greece

The 2023 Hands-on courses will be done using the following ultrasound devices: SonoEye P2, Resona I9 and M9, CERBERO 4.0, Ultrasound System 3300 and CX50. Please consider that similar products from other companies are available on the market.

15
THU

SCIENTIFIC PROGRAMME

HALL GOLD (PLENARY)

17:00-18:15 (CEST)

WELCOME CEREMONY + WELCOME LECTURE

1 Welcome words

*Piergiorgio Messa, Local
Congress President, Italy*



*Loreto Gesualdo, Honorary
Local Congress President,
Italy*



2 Presidential address

*Christoph Wanner, ERA
President, Germany*



3 Diplomas and thanks

*Christoph Wanner, ERA President to Francesca
Mallamaci, Scientific Committee Chair*

4 ERA Awards

Christoph Wanner ERA President

> ERA Award for Outstanding
clinical contributions to
nephrology
*Vladimir Tesar, Czech
Republic*



> ERA Award for Outstanding
basic science contributions
to nephrology)
*Tobias B. Huber,
Germany*



> ERA Award for Research
excellence in nephrology
*Maria Dolores Sanchez-
Niño, Spain*




> ERA Rosanna Gusmano Award
for Young Investigators in
basic science
*Christoph Kuppe,
Germany*



> ERA Stanley Shaldon Award
for Young Investigators in
translational science
*Stefanie Steiger, Germany &
Edouard Fu, The Netherlands*



> ERA Eberhard Ritz Award
for Young Investigators
in clinical science
Olivier Aubert, France



5 Honorary Membership

*Christoph Wanner, ERA
President, Germany
to Carmine Zoccali, Italy*



6 Introduction to the Welcome Lecture

*Francesca Mallamaci,
Scientific Committee
Chair, Italy*



7 Welcome Lecture

*Leonardo in Milano,
Pietro Marani, Italy*



CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

16
FRI

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

WHAT'S NEW IN THE MANAGEMENT OF PRIMARY GLOMERULAR DISEASES?	14
ENSURING OPTIMAL TREATMENTS TO DELAY PROGRESSION CKD IN ROUTINE CLINICAL PRACTICE	14
UPDATES ON CURRENT MANAGEMENT OF CKD – WHAT'S KNEW AND WHERE ARE WE GOING	14
ERA REGISTRY	14
THE RENAL RIDDLE	15
DILEMMAS IN DIALYSIS	15
REJECTION REJECTED	15
LEARN BY PRACTICE ON ANEMIA IN CKD	15
THE ERA PROJECT ON BRAIN AND KIDNEY INTERACTION (CONNECT): PRESENT AND FUTURE	16
NON RESOLVING INFLAMMATION: HOW A DEFENSIVE MECHANISM TRANSFORMS INTO A MAJOR THREAT TO HUMAN HEALTH BASIC / TRANSLATIONA	17
LATE BREAKING CLINICAL TRIALS	17
DECEASED DONOR SELECTION: NEW APPROACHES AND SOLUTIONS	17
CLASSIC AND NON-CLASSIC PLAYERS IN BONE AND VASCULAR DISORDERS IN CKD	17
ADVANCES IN RENAL PHYSIOLOGY 1: NOVEL 'INTRACRINE' REGULATORS OF TUBULAR TRANSPORT	18
ENDOCRINE AND BONE -RELATED STONES	18

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

16
FRI

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

THE ART OF STARING AT URINE: STUDIES IN IGA NEPHROPATHY	18
CALCIUM CONUNDRUMS AND VITAMIN D DILEMMAS	18
AKI: OUTCOMES	19
CREATIVE LABS I: THE CHECK LIST OF SETTING UP A CLINICAL TRIALS	19
HOT TOPICS IN HEMODIALYSIS	20
CKD PREVALENCE AND PROJECTIONS - PREPARING FOR THE STORM?	20
LONG-TERM COMPLICATIONS IN RENAL TRANSPLANTATION	20
LUPUS NEPHRITIS; STILL MANY UNKNOWNNS IN THE TREATMENT	20
HYPERTENSION IN CKD: PROGRESS IN PATHOPHYSIOLOGY AND THERAPEUTIC INNOVATION	21
OBSERVATIONAL STUDIES: WHERE CORRELATION AND CAUSATION GET CONFUSED	21
YOU HAVE TO RECOGNIZE IT BEFORE YOU SEE IT	21
HYPERTENSION: THE ROLE OF 24H ABPM AND REMOTE MONITORING	21
CREATIVE LABS II: ETHICS IN PUBLICATION (RESEARCH ETHICS AND GOOD CLINICAL PRACTICE)	22
PROGRESS IN THE PATHOGENESIS OF NUTRITIONAL DISORDERS IN CKD	23
ELECTRONIC FILES IN NEPHROLOGY: FROM DATA COLLECTION TO ADVANCED DATA MANAGEMENT	23
EXPANDING THE DONOR POOL: A NEW AND BIG CHALLENGE	23

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11


SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

16
FRI

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

NOVEL TREATMENT STRATEGIES FOR RENOPROTECTION	23
MIND THE KIDNEYS: THE RELATIONSHIP BETWEEN CKD AND COGNITION	24
SMALL PATIENTS, BIG DATA	24
AGE AND ACCESS	24
IMMUNOSUPPRESSED CKD PATIENT IN THE ICU	24
MODERATED ORALS + FOCUSED ORALS 	25

HALL GOLD (PLENARY)

08:30-09:45 (CEST)

Symposium 2.1 WHAT'S NEW IN THE MANAGEMENT OF PRIMARY GLOMERULAR DISEASES?

Chairs: Mehmet Sukru Sever &
Serhan Z. Tuglular

1. IgA nephropathy
Rosanna Coppo, Italy
2. Membranous nephropathy
Gema Fernandez, Spain
3. Focal segmental glomerulosclerosis
Paola Romagnani, Italy

HALL AUDITORIUM

08:30-09:45 (CEST)

Symposium 3.1 ENSURING OPTIMAL TREATMENTS TO DELAY PROGRESSION CKD IN ROUTINE CLINICAL PRACTICE

Chairs: Aikaterini Papagianni & Albert Ong

1. Non-steroidal MRAs to the clinics: present and the future
Patrick Mark, United Kingdom
2. Cost effectiveness of implementing SGLT2 inhibitors in routine clinical practice
Hiroshi Nishi, Japan (JSN)



3. Optimizing the use of RASi in advanced CKD
Ana Carina Ferreira, Portugal

HALL SPACE 1 & 2

08:30-09:45 (CEST)

Symposium 6.2 UPDATES ON CURRENT MANAGEMENT OF CKD – WHAT'S KNEW AND WHERE ARE WE GOING

Chairs: Francesca Mallamaci &
Markus Ketteler

1. Development of new therapies to combat kidney disease
Masaomi Nangaku, Japan (ISN)



2. Non-steroidal MRAs in CKD.
Alessandro Zuccalà, Italy
3. CKD, stroke and dementia: are there good news?
Dearbhla Kelly, United Kingdom

HALL SPACE 3 & 4

08:30-09:45 (CEST)

Symposium 0.2 ERA REGISTRY

Chairs: Vianda Stel & Alberto Ortiz

1. Inherited kidney disease project
Alberto Ortiz, Spain
2. Changes in epidemiology of KRT in 2020 – the first year of the COVID-19 pandemic
Kitty Jager, United Kingdom
3. Trajectories of end-of-life in older patients with advanced CKD
Nick Chesnaye, The Netherlands

HALL BROWN 3

08:30-09:45 (CEST)

**Free Communication 23
THE RENAL RIDDLE****Chairs:** *Giovanbattista Capasso & Ionut Nistor***Mini Lecture:** *Mehmet Kanbay, Turkey*
FATTY KIDNEY AND ITS IMPLICATIONS FOR INFLAMMATION AND CKD

AMINOPEPTIDASE A REGULATES ACUTE ANGIOTENSIN DEPENDENT HYPERTENSION

Peter Forster, United States of America

URINARY OROSOMUCOID IS ASSOCIATED WITH ALL-CAUSE MORTALITY IN THE GENERAL POPULATION.

Runa Marie Andreassen, Norway

EXPLORATION OF PROGNOSTIC FACTORS IN DIABETIC NEPHROPATHY WITH NODULAR LESION USING TRANSCRIPTOME ANALYSIS OF HUMAN KIDNEY TISSUES

Toshiyuki Imasawa, Japan♥ IS GFR DECLINE INDUCED BY SGLT-2 INHIBITOR OF CLINICAL IMPORTANCE?
DennisKannenkeril, Germany

HALL BROWN 1&2

08:30-09:45 (CEST)

**Free Communication 13
DILEMMAS IN DIALYSIS****Chairs:** *Björn Meijers & Halima Resic***Mini Lecture:** *Raymond Vanholder, Belgium*
IS THERE ANY PLACE IN THE FUTURE FOR HOME HAEMODIALYSIS?

RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS ACCORDING TO DIALYSIS MODALITY

*Wisam Bitar, Finland***Mini Lecture:** *Giovanni Tripepi, Italy*
EFFECT OF THE DIALYSATE TEMPERATURE ON CLINICAL OUTCOMES IN HEMODIALYSIS PATIENTS

EFFECT OF COMORBIDITIES ON HEALTHCARE EXPENDITURES FOR PATIENTS ON KIDNEY REPLACEMENT THERAPY IN A FRENCH COHORT.

Cécile Couchoud, France

HALL AMBER 1 & 2

08:30-09:45 (CEST)

**Free Communication 19
REJECTION REJECTED****Chairs:** *Sandrine Florquin & Piergiorgio Messa***Mini Lecture:** *Guillaume Canaud, France*
HOW TO MANAGE TRANSPLANT CANDIDATES WITH PRIMARY FSGS FOR A FIRST OR AFTER MULTIPLE TRANSPLANTS

CIRCULATING NEPHRIN AUTOANTIBODIES IN PATIENTS WITH POST-TRANSPLANT RECURRENCE OF PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS

Motoshi Hattori, Japan

INFLUENCE OF CELLULAR INFLAMMATION ON THE OUTCOME OF KIDNEY TRANSPLANTATION AFTER RECURRENCE OF IGA NEPHROPATHY

Teresa Vázquez, Spain

♥ TOCILIZUMAB INDUCTION THERAPY IN KIDNEY TRANSPLANTATION

Sherzod Abdullaev, Uzbekistan

EXCELLENT EFFICACY AND BENEFICIAL SAFETY DURING FIVE YEAR FOLLOW-UP OF RAPID STEROID WITHDRAWAL AFTER RENAL TRANSPLANTATION (HARMONY STUDY)

Julian Stumpf, Germany

HALL AMBER 3 & 4

08:30-09:45 (CEST)

**LEARN BY PRACTICE ON ANEMIA
IN CKD****Chair:** *Mario Cozzolino*

1. Learn by Practice on Anemia in CKD
Lucia del Vecchio, Italy
2. Learn by Practice on Anemia in CKD
Socratis Stoumpos, United Kingdom

16
FRI

SCIENTIFIC PROGRAMME

HALL AMBER 6

10:00-11:00 (CEST)

Symposium 0.9

THE ERA PROJECT ON BRAIN AND KIDNEY INTERACTION (CONNECT): PRESENT AND FUTURE

Chair: *Giovambattista Capasso.*

1. Panel Discussion.

Ivan Rychlik, Czech Republic

Marion Pepin, France

Olivier Godefroy, France

HALL GOLD (PLENARY)

11:00-11:45 (CEST)

Plenary Lecture 1
**NON RESOLVING INFLAMMATION:
 HOW A DEFENSIVE MECHANISM
 TRANSFORMS INTO A MAJOR
 THREAT TO HUMAN HEALTH BASIC
 / TRANSLATIONAL**

Chairs: *Albert Ong & Danilo Fliser*

**Non resolving
 inflammation: How a
 defensive mechanism
 transforms into a major
 threat to human health
 basic / translational**
Alberto Mantovani, Italy



HALL GOLD (PLENARY)

12:00-13:15 (CEST)

Symposium 0.1
LATE BREAKING CLINICAL TRIALS

Chairs: *Giuseppe Remuzzi & Ana Carina Ferreira*

1. THE SGC ACTIVATOR RUNCACIGUAT IS ASSOCIATED WITH A STRONG REDUCTION IN UACR AND GOOD TOLERABILITY IN CKD PATIENTS WITH OR WITHOUT AN SGLT2 INHIBITOR
Ronald Gansevoort, The Netherlands
2. INTRANASAL NICLOSAMIDE FOR PRE-EXPOSURE PROPHYLAXIS AGAINST SARS-COV-2 IN A VULNERABLE, LARGELY VACCINATED RENAL PATIENT POPULATION
Rona Smith, United Kingdom
3. FACTOR XI-A INHIBITION BY OSOCIMAB IN PATIENTS WITH END-STAGE KIDNEY DISEASE ON HEMODIALYSIS (ESKD-HD)
Wolfgang Winkelmayr, United States of America
4. CONVINC: HAEMODIAFILTRATION VERSUS HAEMODIALYSIS FOR MORTALITY, CARDIOVASCULAR EVENTS, AND HOSPITALISATION IN ADULT PATIENTS
Peter J. Blankestijn, The Netherlands
5. LONG-TERM RENAL BENEFIT OVER 2 YEARS WITH NEFECON VERIFIED: THE NEFIGARD PHASE III FULL TRIAL RESULTS
Richard Lafayette, United States of America

HALL AUDITORIUM

12:00-13:15 (CEST)

Symposium 5.1
**DECEASED DONOR SELECTION: NEW
 APPROACHES AND SOLUTIONS**

Chairs: *Christophe Mariat & Marta Crespo*

1. How to select the right donor for the right recipient: guidelines and other considerations.
Piergiorgio Messa, Italy
2. Ethical issue in kidney transplantation
Mehmet Sukru Sever, Turkey
3. New approaches to improve graft viability and implementation.
Gabriel Oniscu, Sweden

HALL SPACE 1 & 2

12:00-13:15 (CEST)

Symposium 4.1
**CLASSIC AND NON-CLASSIC
 PLAYERS IN BONE AND VASCULAR
 DISORDERS IN CKD**

Chairs: *Smeeta Sinha & Pieter Evenepoel*

1. Links Between Bone Fragility Fractures and Vascular Disorders
Jorge Cannata-Andía, Spain
2. Role of Vitamin K in CKD-related Osteoporosis and Vascular Calcification
Maria Fusaro, Italy
3. FGF-23 and CV comorbidities – Vit D or CaSR-agonists
Rainer Oberbauer, Austria

HALL SPACE 3 & 4

12:00-13:15 (CEST)

Symposium 1.2
ADVANCES IN RENAL
PHYSIOLOGY 1: NOVEL
'INTRACRINE' REGULATORS OF
TUBULAR TRANSPORT

Chairs: Robert John Unwin &
Francesco Pesce

1. Renal autocrine and paracrine signaling
Helle Praetorius, Denmark
2. Pharmacological modulation of
sodium-glucose transporters to enhance
ultrafiltration in peritoneal dialysis
Karin Bergling, Sweden
3. Towards clinical application of tubular
transport regulators
Ewout Hoorn, The Netherlands

HALL BROWN 3

12:00-13:15 (CEST)

Symposium 1.1
ENDOCRINE AND BONE -RELATED
STONES

Chairs: Giovanni Gambaro & Marina Noris

1. Nephrolithiasis in hyperparathyroidism
Giuseppe Vezzoli, Italy
2. Nephrolithiasis due to metabolic bone
disease
Nilufar Mohebbi, Switzerland
3. Renal stones and vitamin D: a puzzling
association
Shabbir Moochhala, United Kingdom

HALL BROWN 1 & 2

12:00-13:15 (CEST)

Free Communication 06
THE ART OF STARING AT URINE:
STUDIES IN IGA NEPHROPATHY

Chairs: Antonello Pani & Kate Stevens

Mini Lecture: Paolo Schena, Italy
PREDICTORS OF OUTCOME OF IGA
NEPHROPATHY

♥ EPIDEMIOLOGY OF IGA NEPHROPATHY
AT A UK CENTRE OVER 2 DECADES –
EFFECTS OF IMMUNOSUPPRESSION
Josh Storrar, United Kingdom

★ ESTIMATING DELAY IN TIME TO KIDNEY
FAILURE OR DEATH FOR TREATMENT EFFECTS
ON PROTEINURIA IN IGA NEPHROPATHY
Alex Mercer, Sweden

ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS
OF A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED PH2B STUDY OF
ATACICEPT IN PATIENTS WITH IGAN
Richard Lafayette, United States of America
SUPERIOR PROTEINURIA REDUCTION WITH
SPARSENTAN IN IMMUNOGLOBULIN A
NEPHROPATHY (IGAN): PROTECT STUDY
INTERIM ANALYSIS
Jonathan Barratt, United Kingdom

HALL AMBER 1 & 2

12:00-13:15 (CEST)

Free Communication 17
CALCIUM CONUNDRUMS AND
VITAMIN D DILEMMAS

Chairs: Sandro Mazzaferro &
Hanne Joergensen

Mini Lecture: Mario Cozzolino, Italy
EFFECTS OF CALCIMIMETICS ON LVH

VITAMIN D AND PARATHYROID HORMONE
PREDICT INCIDENT MAJOR ADVERSE
CARDIAC EVENTS IN PATIENTS STARTING
HAEMODIALYSIS: A REAL-WORLD
ANALYSIS
Anirudh Rao, United Kingdom

NO DIFFERENCES IN ALL-CAUSE
OR CARDIOVASCULAR MORTALITY
BETWEEN DIALYSATE CALCIUM OF 1.25
AND 1.50MMOL/L: RESULTS FROM A
EUROPEAN HEMODIALYSIS COHORT
Karlien ter Meulen, The Netherlands

25 HYDROXYVITAMIN D ASSOCIATES
WITH GASTROINTESTINAL BLEEDING IN
DIALYSIS
John Larkin, United States of America

ASSOCIATION BETWEEN CKD-MBD AND
SYMPTOM BURDEN IN OLDER PATIENTS
WITH ADVANCED CKD – RESULTS FROM
THE EQUAL STUDY
Lorenza Magagnoli, Italy

16
FRI

SCIENTIFIC PROGRAMME

HALL AMBER 3 & 4

12:00-13:15 (CEST)

Symposium 7.2 **AKI: OUTCOMES**

Chairs: *Nick Selby & Marlies Ostermann*

- 1.** Mortality risk in patients with AKI - High risk in the long-term as well?
Ziad Massy, France
- 2.** Recurrent AKI after recovery of the first attack
Eva Rodríguez, Spain
- 3.** Transition from AKI to CKD: Transition from bad to worse
Joana Gameiro, Portugal

HALL AMBER 5

12:00-13:15 (CEST)

CREATIVE LABS I: THE CHECK LIST OF SETTING UP A CLINICAL TRIALS

Marcela Fajardo-Moser, Germany

HALL GOLD (PLENARY)

14:45-16:00 (CEST)

Symposium 4.7
HOT TOPICS IN HEMODIALYSIS**Chairs:** *Francesco Locatelli & Ligia Petrica*

1. Hemodialysis hypotension in 2023: a completely preventable complication?
Bernard Canaud, France
2. Hemodiafiltration, Expanded Hemodialysis: which of them for the next future?
Francesco Locatelli, Italy
3. Home therapies - lessons from the Netherlands
Alferso Abrahams, The Netherlands

HALL AUDITORIUM

14:45 - 16:00 (CEST)

Symposium 3.2
CKD PREVALENCE AND PROJECTIONS - PREPARING FOR THE STORM?**Chairs:** *Ana Carina Ferreira & Davide Bolignano*

1. European burden of CKD in a global perspective
Boris Bikbov, Italy
2. Population ageing and how it will impact on CKD epidemics
Kitty Jager, The Netherlands
3. Getting ready: how will this impact on the profession of nephrology and on the delivery of nephrology care?
Fergus Caskey, United Kingdom

HALL SPACE 1 & 2

14:45 - 16:00 (CEST)

Symposium 5.4
LONG-TERM COMPLICATIONS IN RENAL TRANSPLANTATION**Chairs:** *Bente Jespersen & Ilaria Gandolfini*

1. Parathyroidectomy or calcimimetics for tertiary hyperparathyroidism after kidney transplantation?
Martin H de Borst, The Netherlands
2. Prevention and treatment of BK polyoma virus infection: the new TTS guidelines
Hans Hirsch, Switzerland
3. Kidney Fibrosis: Pathogenesis, Biomarkers and Therapeutic Targets
Rikke Nørregaard, Denmark

HALL SPACE 3 & 4

14:45 - 16:00 (CEST)

Symposium 2.3
LUPUS NEPHRITIS; STILL MANY UNKNOWNNS IN THE TREATMENT**Chairs:** *Annette Bruchfeld & Loreto Gesualdo*

1. Immunology and inflammation in lupus nephritis
Eleni Frangou, Cyprus
2. Refractory lupus nephritis: When, why and how to treat
Safak Mirioglu, Turkey
3. Kidney Replacement Therapy and Outcomes in patients with Lupus nephritis
Vladimir Tesar, Czech Republic

HALL BROWN 3

14:45 - 16:00 (CEST)

Symposium 6.1 HYPERTENSION IN CKD: PROGRESS IN PATHOPHYSIOLOGY AND THERAPEUTIC INNOVATION

Chairs: Beatriz Fernandez Fernandez & Robert Ekart

1. Treatment resistant hypertension in pre-dialysis CKD patients: An epidemiological and Clinical Perspective
Andrzej Wiecek, Poland
2. Hypertension and the microbiome in CKD: the critical kidney- gut link
Natalia G Vallianou, Greece
3. Renal denervation in 2023. Striking a balance
Roland E Schmieder, Germany (ESH)



HALL BROWN 1 & 2

14:45 - 16:00 (CEST)

Free Communication 9 OBSERVATIONAL STUDIES: WHERE CORRELATION AND CAUSATION GET CONFUSED

Chairs: Gianluigi Tripepi & Anneke Kramer

Mini Lecture: *Edouard Fu, The Netherlands*
DRAWING CAUSAL INFERENCE
FROM OBSERVATIONAL STUDIES IN
NEPHROLOGY

PREDICTION OF ALL-CAUSE MORTALITY
FOR CHRONIC KIDNEY DISEASE PATIENTS
USING FOUR MODELS OF MACHINE
LEARNING

Nu Thuy Dung Tran, France

♥ ESTIMATED GLOMERULAR FILTRATION
RATE BY FIVE DIFFERING MEASURES,
RACE, GENETIC RISK AND PREDICTION
OF CARDIOVASCULAR DISEASE AND
MORTALITY

Lei Tang, P.R. China

INTEGRATED KIDNEY MARKERS AND
CARDIOVASCULAR MORTALITY: A
SURVIVAL ANALYSIS IN UK BIOBANK
Ryosuke Fujii, Italy

ACUTE KIDNEY INJURY DURATION AND
20-YEAR RISK OF CHRONIC KIDNEY
DISEASE AND CARDIOVASCULAR DISEASE:
A POPULATION-BASED COHORT STUDY
Simon Kok Jensen, Denmark

HALL AMBER 1 & 2

14:45 - 16:00 (CEST)

Free Communication 25 YOU HAVE TO RECOGNIZE IT BEFORE YOU SEE IT

Chairs: *Jolanda Malyszko & Vivekanand Jha*

Mini Lecture: *Laura Cosmai, Italy*
AKI AND ANTI-NEOPLASTIC DRUGS:
WHERE THE ALLIANCE WITH
NEPHROLOGISTS SAVES NEPHRONS

★ ELECTRONIC CREATININE ALERT
SYSTEM. A FIRST STEP TOWARDS
PREVENTING THE HOSPITAL ACQUIRED
ACUTE KIDNEY INJURY
Jordi Soler Majoral, Spain

CLINICAL IMPACT OF UNDIAGNOSED
HOSPITAL ACUTE KIDNEY INJURY
Pasquale Esposito, Italy

ACCURACY OF PLATELET INDICES AS
PREDICTOR OF IN-HOSPITAL MORTALITY
IN PATIENTS WITH ACUTE KIDNEY INJURY
REQUIRING RENAL REPLACEMENT
THERAPY

Melvy June Balasa, The Philippines

HALL AMBER 3 & 4

14:45 - 16:00 (CEST)

Symposium 6.4 HYPERTENSION: THE ROLE OF 24H ABPM AND REMOTE MONITORING

Chairs: *Charles Ferro & Maria Pippias*

1. Is feasible to employ 24h ABPM in clinical practice?
Claudia Torino, Italy
3. Home tele-monitoring and management support of blood pressure
Ikechi Okpechi, Canada
3. Home BP monitoring – can it ever replace 24h ABPM?
Rajiv Agarwal, United States

16
FRI

SCIENTIFIC PROGRAMME

HALL AMBER 5

14:45 - 16:00 (CEST)

**CREATIVE LABS II: ETHICS IN
PUBLICATION (RESEARCH ETHICS
AND GOOD CLINICAL PRACTICE)**

Valerie A. Luyckx, Switzerland

HALL GOLD (PLENARY)

17:00-18:15 (CEST)

Symposium 3.4 PROGRESS IN THE PATHOGENESIS OF NUTRITIONAL DISORDERS IN CKD

Chairs: Peter Stenvinkel & Carla Avesani

1. Renal nutrition in the OMIC era
Peter Stenvinkel, Sweden
2. Reducing salt and promoting dietary K intake; the way to go?
Manuel Ferraro, Italy
3. Modulation of dietary amino acids to retard the progression of CKD
Laetitia Koppe, France

HALL AUDITORIUM

17:00-18:15 (CEST)

Symposium 4.8 ELECTRONIC FILES IN NEPHROLOGY: FROM DATA COLLECTION TO ADVANCED DATA MANAGEMENT

Chairs: Mario Cozzolino & Tamara Jemcov

1. The British health system database and the electronic management of patients with kidney diseases
Dorothea Nitsch, United Kingdom
2. Next generation digital pathology in Nephrology
Laura Barisoni, United States of America
3. The future is now: advanced electronic data system with automatic risk assessment and clinical alerts
Stefano Stuard, Germany

HALL SPACE 1 & 2

17:00-18:15 (CEST)

Symposium 5.3 EXPANDING THE DONOR POOL: A NEW AND BIG CHALLENGE

Chairs: Piergiorgio Messa & Anna Julie Peired

1. Providing information for living donors: what? when? how? who?
Christophe Mariat, France
2. Growing human organs in a dish and in living animals: what is the future of organ transplantation?
Christodoulos Xinaris, Italy
3. The bioartificial kidney: what are the prospects?
Anna Julie Peired, France

HALL SPACE 3 & 4

17:00-18:15 (CEST)

Symposium 2.4 NOVEL TREATMENT STRATEGIES FOR RENOPROTECTION

Chairs: Sokratis Stoumpos & Eleni Frangou

1. Stimulating the protective arm of RAAS
Ariela Benigni, France
2. Extracellular vesicles as new theranostic tools
Lilach Lerman, United States of America
3. Targeting the RNA-binding proteins: a new boundary?
Michael Ignarski, Germany

HALL BROWN 3

17:00-18:15 (CEST)

Free Communication 21 MIND THE KIDNEYS: THE RELATIONSHIP BETWEEN CKD AND COGNITION

Chairs: Davide Viggiano & Marion Pepin

Mini Lecture: Evangelia Ntounousi, Greece
CKD, STROKE AND DEMENTIA – AN
UNHOLY TRINITY?

ACUTE KIDNEY INJURY AND THE RISK OF
DEMENTIA; THE STOCKHOLM CREATININE
MEASUREMENTS (SCREAM) PROJECT.
Hong Xu, Sweden

EFFECTIVENESS AND SAFETY OF
APIXABAN, RIVAROXABAN AND
WARFARIN IN PATIENTS WITH ADVANCED
CKD AND ATRIAL FIBRILLATION:
NATIONWIDE US COHORT STUDY
Edouard Fu, The Netherlands

Mini Lecture: Stella Stabouli, Greece (ESPN)
SUBCLINICAL CARDIOVASCULAR DISEASE
IN CHILDREN WITH CHRONIC KIDNEY
DISEASE. DOES IT MATTER FOR ADULT
OUTCOMES?



HALL BROWN 1 & 2

17:00-18:15 (CEST)

Free Communication 2 SMALL PATIENTS, BIG DATA

Chairs: Ruksana Shroff & Gema Ariceta

Mini Lecture: Gema Ariceta
USE OF COMPLEMENT INHIBITORS IN
PAEDIATRIC PATIENTS

♥ FIRST INTERIM ANALYSIS OF THE
INTERNATIONAL DISTAL RENAL TUBULAR
ACIDOSIS REGISTRY

Marta Giaccari, Italy

♥ ALPORT SYNDROME NATURAL
HISTORY FROM THE RADAR REGISTRY:
ASSOCIATIONS WITH GENE, VARIANT
TYPE AND SEX

Katie Wong, United Kingdom

ECYSCO: A EUROPEAN COHORT
DEDICATED TO CYSTINOSIS

Servais Aude, France

♥ SYSTEMIC OXALOSIS: AN OVERVIEW
OF THE FINDINGS AND PREVALENCE IN
PRIMARY HYPEROXALURIA

Deesker Lisa, The Netherlands

HALL AMBER 1 & 2

17:00-18:15 (CEST)

Free Communication 15 AGE AND ACCESS

Chairs: Marianne Verhaar & Carlo Lomonte

Mini Lecture: Natalie Ebert, Germany
ELDERLY PATIENT WITH ESKD: MANY MORE
PROBLEMS THAN THE SOLUTIONS

A META-ANALYSIS OF VASCULAR ACCESS
OUTCOMES IN HEMODIALYSIS PATIENTS
OVER 75 YEARS OLD

Alexandra Ntemka, Greece

DETERMINATION OF PREDICTORS OF
OUTCOMES FOLLOWING VASCULAR
ACCESS CONVERSION: WHICH PATIENTS
BENEFIT MOST?

Amun Hofmann, Austria

ARTERIOVENOUS FISTULA BLOOD FLOW
ESTIMATION THROUGH AI MODEL
EXPLOITING PATIENT'S ROUTINELY
COLLECTED DATA

Francesco Bellocchio, Italy

EVALUATION OF REMOTE MONITORING
OF HAEMODIALYSIS VASCULAR ACCESS
FOR PREDICTION OF STENOSIS AND
THROMBOTIC VASCULAR EVENTS

Dimitrios Poulidakos, United Kingdom

HALL AMBER 3 & 4

17:00-18:15 (CEST)

Symposium 7.3 IMMUNOSUPPRESSED CKD PATIENT IN THE ICU

Chairs: Norbert Lameire & Hans-Joachim
Anders

1. Management of immunosuppressant(s):
Why-when-how: Maintain- stop- modify?
Hans-Joachim Anders, Germany
2. AKI superimposed on CKD in the ICU setting
Norbert Lameire, Belgium
3. Who will manage the patient: Intensivist or
the nephrologist?
Bairbre McNicholas, Ireland



08:30 - 09:45 (CEST)

12:00 - 13:15 (CEST)

14:45 - 16:00 (CEST)

17:00 - 18:15 (CEST)

HALL AMBER 6

MODERATED ORALS 1.1

MODERATED ORALS 1.2

MODERATED ORALS 1.3

MODERATED ORALS 1.4

HALL FOCUSSED ORALS

FOCUSSED ORALS 1.1

FOCUSSED ORALS 1.2

FOCUSSED ORALS 1.3

FOCUSSED ORALS 1.4

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

**17
SAT**

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

CKD PROGRESSION: BETWEEN THE OLD AND THE NEW	29
CLINICAL ISSUES IN PERITONEAL DIALYSIS I	29
2023 PEARLS OF NDT AND CKJ	29
ARE THERE NEW APPROACHES TO PREVENT AND TREAT AB-MEDIATED REJECTION	29
AN SGLT-2 INHIBITOR A DAY KEEPS THE DOCTOR AWAY	30
IDENTIFYING THE SWEET SPOT IN DIABETIC KIDNEY DISEASE	30
IS CKD PART OF THE LONG COVID SYNDROME?	30
LEARN BY PRACTICE ON HYPERKALEMIA IN CKD	30
CREATIVE LABS III: HOW TO RUIN YOUR PRESENTATION	31
ERA GENERAL ASSEMBLY	32
SEX, SCIENCE, MEDICINE AND GLOBAL (KIDNEY) HEALTH: WHERE WE ARE AND WHERE WE ARE GOING	32
C3 GLOMERULOPATHY	32
VOLUME CONTROL REMAINS AN UNMET CLINICAL NEED IN CKD AND HEMODIALYSIS PATIENT	33
ADVANCES IN RENAL PHYSIOLOGY 2: NEWER HOMEOSTATIC MECHANISMS CONTROLLING KIDNEY FUNCTION	33
DIABETIC KIDNEY DISEASE UPDATE: GO BEYOND BORDERS	33
CONTEMPORARY AKI MANAGEMENT	33

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

**17
SAT**

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

MECHANISMS OF CKD PROGRESSION AND COMPLICATIONS: UNMASKING THE MYSTERY	34
PRE-EMPTIVE TRANSPLANTATION AND WHICH DONORS TO CHOOSE	34
SOMETHING RARE, SOMETHING SPECIAL	34
EGFR MEASUREMENTS IN CLINICAL PRACTICE	34
CKD DIAGNOSIS AND CARE IN THE PRIMARY CARE SETTING	35
INNOVATION IN DIALYSIS AND CLINICAL APPLICATION	36
UNMET NEEDS IN ADVANCED CKD: IMPROVING MAJOR SYMPTOMS AND QOL	36
CAN WE PREDICT GRAFT OUTCOMES?	36
POLYCYSTIC KIDNEY DISEASE: A MULTIFACETED DISEASE	36
DIALYSIS IN AKI: STILL AN ENDLESS STORY OR HAVE ISSUES BEEN CLARIFIED?	37
THE PERITONEAL PERSPECTIVE	37
NAVIGATING THE IGA NEPHROPATHY PATHWAY	37
TRANSPLANT TALES	37
ARMED CONFLICTS, KIDNEY PATIENTS AND NEPHROLOGISTS	38
EDUCATION IN NEPHROLOGY WHERE ARE WE GOING? (NPATH)	38
LATE BREAKING CLINICAL TRIAL	38
ASN HIGHLIGHTS	39

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

**17
SAT**

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

HYPERTENSION IN DIALYSIS PATIENTS: HOW TO MEASURE IT AND HOW TO TREAT IN 2023?	39
PREGNANCY, COMPLICATIONS AND IMPLICATIONS ON TREATMENT	39
HEART DISEASE IN CKD	39
CARDIO-VASCULAR COMPLICATIONS IN RENAL TRANSPLANTATION: STILL A NEGLECTED FIELD?	40
THE RENAL REVOLUTION: TACKLING RENAL DISEASE ON A GLOBAL SCALE	40
DIALYSIS INSIGHTS AND INNOVATIONS	40
THE ANCA VASCULITIS VARIETY SESSION	40
CREATIVE LABS IV: BALANCING PARENTHOOD AND CAREER	41

HALL GOLD (PLENARY)

08:30-09:45 (CEST)

Symposium 3.3 CKD PROGRESSION: BETWEEN THE OLD AND THE NEW

Chairs: Manuel Anibal A. Ferreira & Pieter Evenepoel

1. Low GFR and ageing; distinguish physiological and disease-related
Pierre Delanaye, Belgium
2. Does COVID-19 really induce CKD?
Rafael Kramann, Germany
3. Climate change, air pollution and kidney disease
Valerie Luyckx, Switzerland

HALL AUDITORIUM

08:30-09:45 (CEST)

Symposium 4.2 CLINICAL ISSUES IN PERITONEAL DIALYSIS I

Chairs: Monika Lichodziejewska-Niemierko & Edwina Brown

1. Genetic variants that predict peritoneal ultrafiltration
Rajnish Mehrotra, United States of America
2. Peritoneal dialysis in heart failure and in AKI. An evidence based approach
Daniela Ponce, Brazil
3. Hard facts: guidelines in peritoneal dialysis
Mark Lambie, United Kingdom

HALL SPACE 1 & 2

08:30-09:45 (CEST)

Symposium 0.4 2023 PEARLS OF NDT AND CKJ

Chairs: Denis Fouque & Maria Soler

1. NDT Editor selects 2 Speakers from associate Editors
Davide Bolognani, Italy
Emilie Cornec-Le Gall, France
2. CKJ Editor selects 2 Speakers from the Editorial Board
Parminder Judge, United Kingdom
Andreas Kronbichler, United Kingdom

HALL SPACE 3 & 4

08:30-09:45 (CEST)

Symposium 5.5 ARE THERE NEW APPROACHES TO PREVENT AND TREAT AB- MEDIATED REJECTION?

Chairs: Bruno Watschinger & Z. Serhan Tuglular

1. Imlifidase for HLA-sensitised patients
Andreas Kronbichler, United Kingdom
2. Complement inhibitors for the prevention and treatment of acute Ab-mediated rejection
Marta Crespo, Spain
3. New concepts in the prevention and treatment of chronic Ab-mediated rejection
Farsad Eskandary, Austria

HALL BROWN 3

08:30-09:45 (CEST)

**Free Communication 10
AN SGLT-2 INHIBITOR A DAY
KEEPS THE DOCTOR AWAY****Chairs:** Richard Haynes & Samira Bell**Mini Lecture:** David Wheeler,
United Kingdom
SGLT-2 INHIBITORS IN GLOMERULAR
DISEASEEFFECTS OF EMPAGLIFLOZIN ON KIDNEY
AND CARDIAC MRI MEASURES IN
PATIENTS WITH CHRONIC KIDNEY DISEASE
*Parminder Judge, United Kingdom*EFFECTS OF EMPAGLIFLOZIN ON FLUID
OVERLOAD IN CHRONIC KIDNEY DISEASE:
AN EMPA-KIDNEY BIOIMPEDANCE
SUBSTUDY
*Kaitlin Mayne, United Kingdom*REASONS FOR DIALYSIS INITIATION AND
SAFETY OF DAPAGLIFLOZIN AMONG
DIALYSIS PARTICIPANTS: NEW INSIGHTS
FROM DAPA-CKD
Hidido Lambers Heerspink, The Netherlands♥ FINERENONE ADDED TO RAS/
SGLT2 BLOCKADE FOR NON-DIABETIC
CHRONIC KIDNEY DISEASE. RESULTS
OF A PRECLINICAL DOUBLE-BLINDED
RANDOMIZED CONTROLLED TRIAL.
Zhihui Zhu, Germany

HALL BROWN 1 & 2

08:30-09:45 (CEST)

**Free Communication 22
IDENTIFYING THE SWEET SPOT
IN DIABETIC KIDNEY DISEASE****Chairs:** Esteban Porrini & Mads Hornum**Mini Lecture:** Tetsuhiro Tanaka, Japan (JSN)
OXYGEN METABOLISM IN DIABETIC
KIDNEY DISEASE♥ IDENTIFICATION OF KEY GENES IN
DIABETIC NEPHROPATHY BASED ON LIPID
METABOLISM
*Meng Yang, P.R. China*EFFICACY AND SAFETY OF COTADUTIDE,
A DUAL GLP1-GLUCAGON RECEPTOR
AGONIST, IN PATIENTS WITH CHRONIC
KIDNEY DISEASE AND T2DM
*Viknesh Selvarajah, United Kingdom***Mini Lecture:** Sih Min Tan, Australia
(ANZSN)
THE ROLE OF COMPLEMENT C5A
RECEPTOR 1 IN DIABETIC KIDNEY DISEASE.

HALL AMBER 1 & 2

08:30-09:45 (CEST)

**Free Communication 26
IS CKD PART OF THE LONG
COVID SYNDROME?****Chairs:** Ronald Gansevoort &
Marianne Verhaar**Mini Lecture:** Faeq Husain-Syed, Germany
AKI-CKD TRANSITION AFTER COVID-19 -
HOW TO ASSESS?REGIONAL VARIATION OF ACUTE KIDNEY
INJURY IN COVID-19 IN ENGLAND
*Nitin Kolhe, United Kingdom*PREDICTION OF COVID-19 SEVERITY IN
HOSPITALIZED PATIENTS USING URINARY
PROTEOMICS AND MACHINE LEARNING
*Nanditha Anandakrishnan, United States of
America*SECONDARY BACTERIAL AND FUNGAL
INFECTIONS IN COVID-19 PATIENTS WITH
ACUTE KIDNEY INJURY AND RELATION WITH
CYTOKINE STORM SYNDROME
Radulescu Daniela, Romania★ EFFICACY OF PAXLOVID WITHIN 5 DAYS
VERSUS 5 DAYS AFTER DIAGNOSIS IN
COVID-19 PATIENTS WITH CHRONIC KIDNEY
DISEASE
Wenjuan Yu, P.R. China

HALL AMBER 3 & 4

08:30-09:45 (CEST)

**LEARN BY PRACTICE ON
HYPERKALEMIA IN CKD****Chair:** Pantelis Sarafidis

1. Learn by practice on Hyperkalemia in CKD
Andrea Galassi, Italy
2. Learn by practice on Hyperkalemia in CKD
Kieran McCafferty, United Kingdom

17
SAT

SCIENTIFIC PROGRAMME

HALL AMBER 5

08:30-09:45 (CEST)

**CREATIVE LABS III: HOW TO
RUIN YOUR PRESENTATION**

Jürgen Floege, Germany

HALL GOLD (PLENARY)

09:45-11:00 (CEST)

ERA GENERAL ASSEMBLY

The ERA 2023 Ordinary General Assembly (OGA) will take place on June 17, 2023, from 9.45 to 11.00 (CEST) in the Gold Room (Plenary) of the MICO – Milan Convention Centre - in Milan and virtually. Kindly note that active ERA Full* Members have voice and vote during the Assembly, instead active ERA Associate and Corporate Members have voice but cannot vote.
*Please note that only active ERA Full Members (not Corporate) may vote.

**VOTE!****Part I - 09.30-09.40**

OPENING

Welcome, *Christoph Wanner (ERA President)*

- Minutes of the 59th General Assembly
Ivan Rychlik (Secretary-Treasurer)

Part II - 09.40-10.30

- Report from the President
Christoph Wanner
- Report from the Secretary-Treasurer
Ivan Rychlik
- Report from the Renal Science Chair
Danilo Fliser
- Report from the Clinical Nephrology Governance Chair
Alberto Ortiz

Part III - 10.30-10.45

- Election of the Ordinary Council Member (two vacancy)
Christoph Wanner
- Venue and date of the 2025 ERA Congress
Christoph Wanner
- Date and venue of the next General Assembly
Ivan Rychlik
- Any other business
FERA awards,
Ivan Rychlik

CLOSURE, *Christoph Wanner*

HALL GOLD (PLENARY)

11:00-11:45 (CEST)

Plenary Lecture 2
SEX, SCIENCE, MEDICINE AND
GLOBAL (KIDNEY) HEALTH:
WHERE WE ARE AND WHERE WE
ARE GOING

Chairs: *Roser Torra & Annette Bruchfeld*

Sex, Science, Medicine
and Global (kidney)
Health: where we are
and where we are
going

Adeera Levin, Canada



HALL GOLD (PLENARY)

12:00-13:15 (CEST)

Symposium 2.2
C3 GLOMERULOPATHY

Chairs: *Dimitrios Goumenos & Claudio Ponticelli*

- C3 glomerulopathy - are some complement variants more pathogenic than others?
Elena Giocechea De Jorge, Spain
- Unravelling the involvement of complement in C3 glomerulopathy pathogenesis and implication in complement therapeutics
Antonello Pani, Italy
- Management strategies for recurrence of C3 glomerulopathy pre and post renal transplantation
Manuel Praga, Spain

HALL AUDITORIUM

12:00-13:15 (CEST)

Symposium 4.5
VOLUME CONTROL REMAINS AN UNMET CLINICAL NEED IN CKD AND HEMODIALYSIS PATIENT

Chairs: Gérard Michel London & Nada Dimkovic

1. Sodium intake target in current CKD guidelines, instruments for self-measurement of urinary sodium and adherence to low salt diets
Carmine Zoccali, Italy
2. Bio-impedance: a valid method to guide Ultrafiltration prescription during hemodialysis
Ulrich Moissl, Belgium
3. How to diagnose and treat Heart Failure in dialysis patients
Gérard Michel London, France

HALL SPACE 1 & 2

12:00-13:15 (CEST)

Symposium 1.3
ADVANCES IN RENAL PHYSIOLOGY 2: NEWER HOMEOSTATIC MECHANISMS CONTROLLING KIDNEY FUNCTION

Chairs: Hans-Joachim Anders & Rezan Topaloglu

1. Circadian control of blood pressure rhythmicity
Jessica Ivy, United Kingdom
2. Circadian control of nephron metabolism
Yohan Bignon, Switzerland
3. New insight into Kidney-heart connection: magnesium as a player
Francesco Trepiccione, Italy

HALL SPACE 3 & 4

12:00-13:15 (CEST)

Symposium 6.5
DIABETIC KIDNEY DISEASE UPDATE: GO BEYOND BORDERS

Chairs: Fernandez Fernandez Beatriz & Francesco Trevisani

1. Beyond trials: what can routine care data tell us about the safety and effectiveness of novel antidiabetic medications?
Juan Jesus Carrero, Sweden
2. Predicting response to dapagliflozin: results in light of post-hoc analysis of DAPA-CKD
Hiddo J L Heerspink, The Netherlands
3. Role of insulin therapy in DKD in the era of new antidiabetic drugs
Esteban Porrini, Spain

HALL BROWN 3

12:00-13:15 (CEST)

Symposium 7.4
CONTEMPORARY AKI MANAGEMENT

Chairs: Danilo Fliser & Jolanta Malyszko

1. Prediction of AKI: biomarkers, clinical models or both?
Greet De Vlieger, Belgium
2. Artificial intelligence: Can it guide management of AKI patients?
Jay L. Koyner, United States of America
3. As climate changes: EU get ready for subtropical causes of AKI
Vivekanand Jha, India

HALL BROWN 1 & 2

12:00-13:15 (CEST)

Free Communication 11
MECHANISMS OF CKD
PROGRESSION AND
COMPLICATIONS: UNMASKING
THE MYSTERY

Chairs: Goce Spasovski & Kathrin Eller

Mini Lecture: Olga Balafa, Greece
 SUBCLINICAL ACID RETENTION AND CKD
 PROGRESSION

♥ CAROTID PLAQUE THICKNESS PREDICTS
 CARDIOVASCULAR EVENTS AND DEATH IN
 PATIENTS WITH CHRONIC KIDNEY DISEASE
 Sasha Saurbrey Bjergfelt, Denmark

FIRST IDENTIFICATION AND
 CHARACTERIZATION OF MICROPLASTICS
 IN HUMAN KIDNEY AND URINE
 Ottavia Exacoustos, Italy

BIO-CONDUCTIVITY MEASUREMENTS
 ENABLES PORTABLE AND SELF-
 ADMINISTRATED CHRONIC KIDNEY
 DISEASE SCREENING AND MONITORING
 Eddie Wong, Hong Kong, P.R. China

THE ROLE AND MECHANISM OF EZH2 IN
 VASCULAR CALCIFICATION ASSOCIATED
 WITH CHRONIC KIDNEY DISEASE
 Lin Pinglan, P.R. China

HALL AMBER 1 & 2

12:00-13:15 (CEST)

Free Communication 18
PRE-EMPTIVE
TRANSPLANTATION AND
WHICH DONORS TO CHOOSE

Chairs: David Ferenbach &
 Evangelia Ntounousi

Mini Lecture: Vianda Stel,
 The Netherlands
 TRANSPLANT SURVIVAL BENEFIT – DOES IT
 APPLY TO ALL PATIENT SUBGROUPS?

★ RACIAL DISPARITY AND KIDNEY
 FUNCTION IN LIVING KIDNEY DONORS
 Ekamol Tantissattamo, United States of
 America

★ EXTENDED VALIDATION OF THE
 IBOX IN REAL LIFE SETTING, DIFFERENT
 TRANSPLANT SYSTEMS AND CLINICAL
 TRIALS: THE IBOX EXTENDED TRIAL
 Sofia Naser, France

🌐 NEXT GENERATION SEQUENCING:
 FROM BANFF SCORE MOLECULAR
 SIGNATURES AND CLASSIFIERS TO
 PREDICTED HISTOLOGICAL ARCHETYPES
 OF KIDNEY BIOPSIES
 Esteban Cortes Garcia, France

★ PROGNOSTIC VALUE OF A POSITIVE
 CROSSMATCH BEFORE DESENSITIZATION
 IN A COHORT OF HIGHLY-SENSITIZED
 PATIENTS
 Johan Noble, France

HALL AMBER 3 & 4

12:00-13:15 (CEST)

Free Communication 3
SOMETHING RARE, SOMETHING
SPECIAL

Chairs: Maria Vanessa Perez Gomez &
 Lucile Figueres

Mini Lecture: Hyoungnae Kim, Korea,
 Rep. of South (KSN)
 EXOSOMAL RNAS IN KIDNEY DISEASE



NOVEL DOMINANT ALG5 VARIANT IN TWO
 UNRELATED FAMILIES WITH LATE-ONSET
 ADPKD AND ATYPICAL TUBULOINTERSTITIAL
 CHANGES

Elhussein Elhassan, Ireland

THE ROLE OF C5AR VERSUS C3 IN
 THROMBOTIC MICROANGIOPATHY,
 ISCHEMIC KIDNEY NECROSIS, AND ACUTE
 KIDNEY INJURY INDUCED BY CHOLESTEROL
 CRYSTAL EMBOLISM

Danyang Zhao, Germany

★ EXPRESSION OF THE COLLAGEN IV A345
 MOLECULE ALONG THE RENAL TUBULE IN
 HEALTH AND DISEASE

Loderbauer Lisa, Germany

CHK-336, A FIRST-IN-CLASS ORALLY
 ADMINISTERED LDH INHIBITOR: SAFETY, PK
 AND TARGET ENGAGEMENT IN A FIRST-
 IN-HUMAN PHASE 1 HEALTHY VOLUNTEER
 STUDY

Vincent Tong, United States of America

HALL AMBER 5

12:00-13:15 (CEST)

Symposium 0.12
EGFR MEASUREMENTS IN
CLINICAL PRACTICE

Chair: Christophe Mariat

1. Panel discussion
 Pierre Delanaye, Belgium
 Etienne Cavalier, Belgium
 Elke Schaeffner, Germany

17
SAT

SCIENTIFIC PROGRAMME

HALL AMBER 7

12:30-13:30 (CEST)

CKD DIAGNOSIS AND CARE IN THE PRIMARY CARE SETTING

Chairs: *Alexander Rosenkranz & Jaquie Finn*

1. Panel Discussion

Naresh Kanumilli, United Kingdom

Daniel Gallego Zurro, Spain

Kieran McCafferty, United Kingdom

This symposium is organized by the European
Renal Association Curatorium (ERAC)



HALL GOLD (PLENARY)

14:45-16:00 (CEST)

Symposium 4.4 INNOVATION IN DIALYSIS AND CLINICAL APPLICATION

Chairs: Carlo Basile & Maria Haller

1. Can the clearance of protein-bound uremic toxins be enhanced: theoretical and practical aspects.
Peter Kotanko, United States of America
2. Innovations in dialysis: MI-TRAM (Multi-compatible Implantable Toxin Removal Augmentation Module with fluid sensing) and new approaches
Karin Gerritsen, The Netherlands
3. Incremental and twice- weekly longer hemodialysis. Testable in randomized clinical trials?
Kamiar Kalantar Zadeh, United States of America

HALL AUDITORIUM

14:45 - 16:00 (CEST)

Symposium 3.5 UNMET NEEDS IN ADVANCED CKD: IMPROVING MAJOR SYMPTOMS AND QOL

Chairs: Vianda Stel & Goce Spasovski

1. Pathogenesis and potential management strategies of uremia-induced cognitive impairment
Davide Viggiano, Italy
2. Managing chronic pain in persons with CKD
Samira Bell, United Kingdom
3. Fatigue in CKD: causes, consequences and management
Lucile Parker Gregg, United States of America

HALL SPACE 1 & 2

14:45 - 16:00 (CEST)

Symposium 5.6 CAN WE PREDICT GRAFT OUTCOMES?

Chairs: Giuseppe Grandaliano & Carmen Lefaucheur

1. What the iBox is and is it useful for clinical decision-making?
Oliver Aubert, France
2. Immunosuppression minimization; Why? - Who? - When? - How?
Nuria Montero, Spain
3. Will biomarkers help us to predict graft outcomes?
Elisabeth Van Loon, Belgium

HALL SPACE 3 & 4

14:45 - 16:00 (CEST)

Symposium 1.5 POLYCYSTIC KIDNEY DISEASE: A MULTIFACETED DISEASE

Chairs: Giovambattista Capasso & Alessandra Boletta

1. Metabolic Reprogramming in Polycystic Kidney Disease
Alessandra Boletta, Italy
2. Genetic Heterogeneity in Autosomal Dominant Polycystic Kidney Disease
Emilie Cornec-LeGall, France
3. Metabolism and Dietary Interventions in ADPKD
Roman-Ulrich Müller, Germany

HALL BROWN 3

14:45 - 16:00 (CEST)

Symposium 7.1 DIALYSIS IN AKI: STILL AN ENDLESS STORY OR HAVE ISSUES BEEN CLARIFIED?

Chairs: Marianne Verhaar & Laura Cosmai

1. STARRT-AKI Trial.
Marlies Ostermann, United Kingdom
2. AKIKI 2 trial
Stéphane Gaudry, France
3. What do metaanalyses say?
Jan Kielstein, Germany

HALL BROWN 1 & 2

14:45 - 16:00 (CEST)

Free Communication 16 THE PERITONEAL PERSPECTIVE

Chairs: Angela Wang &
Monika Lichodziejewska-Niemierko

Mini Lecture: Edwina Brown, United
Kingdom (ISPD)
ASSISTED PD IN EUROPE: CALL FOR
INCREASED AND EQUAL ACCESS



**IN VIVO EVALUATIONS ON THE
PROTECTIVE EFFECTS OF NEW
FORMULATIONS FOR PERITONEAL
DIALYSIS ADOPTING A POWERFUL
MULTI-PHOTON MICROSCOPY BASED
APPROACH**
Luciano D'Apolito, Italy

**PERITONEAL DIFFUSE PODOPLANIN
EXPRESSION IS ASSOCIATED WITH SEVERE
ARTERIOLOPATHY IN CHILDREN ON
PERITONEAL DIALYSIS**
Maria Bartosova, Germany

**PERITONEAL DIALYSIS ADDITIVE REDUCES
TRANSPERITONEAL LOSS OF BLOOD
MICROPARTICLE AND EXTRACELLULAR
MATRIX PROTEINS IN A CONTROLLED
CROSSOVER TRIAL**
Fabian Eibensteiner, Austria

**AUTOPHAGY PATHWAY ACTIVATION
IN IMMUNE-INFLAMMATORY CELLS OF
PERITONEAL DIALYSIS PATIENTS.**
Gianluigi Zaza, Italy

HALL AMBER 1 & 2

14:45 - 16:00 (CEST)

Free Communication 4 NAVIGATING THE IGA NEPHROPATHY PATHWAY

Chairs: Gema Maria Fernandez Juarez &
Vladimir Tesar

Mini Lecture: Hitoshi Suzuki, Japan (JSN)
THE PHENOTYPIC DIFFERENCE OF IGA
NEPHROPATHY DEPENDS ON MOLECULAR
MECHANISMS



**INCIDENCE AND OUTCOMES OF KIDNEY
REPLACEMENT THERAPY FOR END-STAGE
KIDNEY DISEASE DUE TO PRIMARY
GLOMERULONEPHRITIS IN THE ERA REGISTRY**
Samar Abd ElHafeez, Egypt

**♥ INVESTIGATING THE ROLE OF CFH
VARIANTS AND HAPLOTYPES AS A RISK
FACTOR OF IGA NEPHROPATHY IN A
FRENCH COHORT**
Anna Duval, France

**COVID VACCINE RESPONSES DURING
SIBEPRENIMAB TREATMENT OF IGA
NEPHROPATHY (IGAN): AN INTERIM
ANALYSIS**
Kieran McCafferty, United Kingdom

**MODELLING LONG-TERM OUTCOMES
FOR PATIENTS WITH IMMUNOGLOBULIN A
NEPHROPATHY (IGAN) FROM SHORT-TERM
PROTEINURIA DATA**
Mark Bensink, United States of America

HALL AMBER 3 & 4

14:45 - 16:00 (CEST)

Free Communication 20 TRANSPLANT TALES

Chairs: Orsolya Cseprenkai & Licia Peruzzi

Mini Lecture: Gaetano La Manna, Italy
THROMBOTIC MICROANGIOPATHY AFTER
KIDNEY TRANSPLANTATION

**DONOR-DERIVED CELL-FREE DNA (DD-
CDNA) AS A NON-INVASIVE BIOMARKER
OF KIDNEY ALLOGRAFT REJECTION IN
PEDIATRIC KIDNEY TRANSPLANTATION.**
Julien Hogan, France

**BELATACEPT OUTCOMES IN PEDIATRIC
KIDNEY TRANSPLANTATION: AN
INTERNATIONAL MULTICENTER STUDY.**
Julien Hogan, France

**IMPACT OF DARATUMUMAB & BELATACEPT
ON HLA ANTIBODIES IN KIDNEY
TRANSPLANT CANDIDATES WITH 100%
CPRA: EARLY RESULTS OF ATTAIN (ITN090ST)**
Flavio Vincenti, United States of America

**HEPATITIS B VIRUS REACTIVATION IN KIDNEY
TRANSPLANT RECIPIENTS TREATED WITH
BELATACEPT**
Chloe Schwarz, France

HALL AMBER 5

14:45 - 16:00 (CEST)

**ARMED CONFLICTS,
KIDNEY PATIENTS AND
NEPHROLOGISTS****Chairs:** Raymond Vanholder &
Mehmet Şükrü Sever

1. Being a nephrologist during an armed conflict
Dmytro Ivanov, Ukraine
2. Case of displaced patients with kidney disease during the war in Ukraine
Andrzej Wiecek, Poland
3. Learning to mitigate the impact of war - a report of Renal Disaster Relief Task Force of ERA
Serhan Tuğlular, Turkey
4. The most devastating pediatric renal disaster: the February 6th, 2023 Kahramanmaraş/Türkiye earthquake
Sevcan Azime Bakkaloglu, Turkey

HALL AMBER 6

14:00-17:00 (CEST)

**Symposium 0.10
EDUCATION IN NEPHROLOGY
WHERE ARE WE GOING?
(NPATH)****Chairs:** Loreto Gesualdo & Carlo Lomonte

1. Panel discussion
Loreto Gesualdo, Italy
Jose Ibeas, Spain
Maurizio Gallieni, Italy
2. N-PATH Trainees Award Ceremony

HALL AUDITORIUM

16:10-16:55 (CEST)

**Symposium 0.11
LATE BREAKING CLINICAL
TRIALS****Chairs:** Ronald Gansevoort & Roser Torra

1. 36-WK EFFICACY & SAFETY OF ATACICEPT 150MG IN THE ORIGIN RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY IN IGAN AND PERSISTENT PROTEINURIA
Richard Lafayette, United States of America
2. GFR SLOPE AS A SURROGATE ENDPOINT FOR KIDNEY FAILURE IN CLINICAL TRIALS: AN UPDATED META-ANALYSIS
Hiddo Lambers Heerspink, The Netherlands
3. EXERCISE DURING HEMODIALYSIS IN PATIENTS WITH CHRONIC KIDNEY FAILURE
Gero Von Gersdorff, Germany

HALL GOLD (PLENARY)

17:00-18:15 (CEST)

**Symposium 0.3
ASN HIGHLIGHTS****Chairs:** Susan Quaggin

1. Diabetic Kidney Disease Highlights
Catherine Godson, United States of America
2. Glomerular Diseases Highlights
Kirk Campbell, United States of America
3. Hypertension and Cardiorenal Disorders Highlights
Karen Griffin, United States of America



HALL AUDITORIUM

17:00-18:15 (CEST)

**Symposium 4.6
HYPERTENSION IN DIALYSIS
PATIENTS: HOW TO MEASURE
IT AND HOW TO TREAT IN
2023?****Chairs:** Carmine Zoccali & Pantelis Sarafidis

1. Assessing fluid volume in dialysis - is lung ultrasound the emerging standard?
Pantelis Sarafidis, Greece
2. BP target in hemodialysis patients: approach to an unsolved dilemma.
Indranil Dasgupta, United Kingdom
3. Dialysis and Home Dialysis in the pandemic years
Helena Rydell, Sweden

HALL SPACE 1 & 2

17:00-18:15 (CEST)

**Symposium 1.4
PREGNANCY, COMPLICATIONS
AND IMPLICATIONS ON
TREATMENT****Chairs:** Andreas Kronbichler & Annette Bruchfeld

1. Safety and uncertainty of immunosuppression during pregnancy
Sarah Gleeson, United Kingdom
2. From preeclampsia to glomerular disease: spectrum of kidney diseases during pregnancy
Annette Bruchfeld, Sweden
3. CKD progression in transplanted and non-transplanted patients during and after pregnancy
Giorgina Piccoli, France

HALL SPACE 3 & 4

17:00-18:15 (CEST)

**Symposium 6.3
HEART DISEASE IN CKD****Chairs:** Lucia Del Vecchio & José Manuel Valdivielso Revilla

1. A special approach for aortic stenosis (TAVI or SAVR) in CKD patients.
Mattia Lunardi, Ireland
2. Cardiac Metabolic Remodeling in CKD
Dunja Aksentijevic, United Kingdom
3. Heart and kidney disease: an intriguing liaison.
Anna Price, United Kingdom

HALL BROWN 3

17:00-18:15 (CEST)

Symposium 5.7 CARDIO-VASCULAR COMPLICATIONS IN RENAL TRANSPLANTATION: STILL A NEGLECTED FIELD?

Chairs: Luuk Hilbrands & Gabriel Oniscu

1. Post transplant diabetes mellitus (PTDM): can it be actively prevented and how?
Elisabeth Schwaiger, Austria
2. SGLT2 inhibitors: should be used for all renal transplant patients or when and in whom?
Chiara Caletti, Italy
3. How to best treat post-Tx hypertension? What are the gap of knowledge?
Jean-Michel Halimi, France (ESH)



HALL BROWN 1 & 2

17:00-18:15 (CEST)

Free Communication 8 THE RENAL REVOLUTION: TACKLING RENAL DISEASE ON A GLOBAL SCALE

Chairs: Samar Abd ElHafeez & Olga Balafa

Mini Lecture: Samar Abd ElHafeez, Egypt
CKD IN AFRICA: A PUBLIC HEALTH PRIORITY

♥ PREVALENCE OF UNRECOGNIZED CHRONIC KIDNEY DISEASE IN THE LOLLAND-FALSTER HEALTH STUDY: A POPULATION-BASED STUDY IN A RURAL-PROVINCIAL AREA OF DENMARK.
Ebba Mannheimer, Denmark

INTERNATIONAL VARIATIONS IN TRANSITION OF CARE PRACTICES AND TWO-YEAR OUTCOMES IN ADVANCED CHRONIC KIDNEY DISEASE
Natalia Alencar de Pinho, France

DOES AV FISTULA FORMATION DELAY TIMING OF INITIATION OF KIDNEY REPLACEMENT THERAPY IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE?
Luis Loureiro Harrison, United Kingdom

HEMOGLOBIN VARIABILITY AND ADVERSE CLINICAL EVENTS IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE AND ANEMIA IN CONTINUOUS CARE
Suguru Okami, Japan

HALL AMBER 1 & 2

17:00-18:15 (CEST)

Free Communication 14 DIALYSIS INSIGHTS AND INNOVATIONS

Chairs: Francesco Locatelli & Sanjin Racki

Mini Lecture: Jeong-Hoon Lim, Korea, Rep. of South (KSN)
REMOVAL OF LARGE-MIDDLE MOLECULES: CLINICAL IMPACT IN HEMODIALYSIS PATIENTS



CAN A BLOOD TEST FOR MIDDLE MOLECULES BE USED TO MEASURE RESIDUAL KIDNEY FUNCTION TO PERFORM INCREMENTAL DIALYSIS?
Usama Butt, United Kingdom

THE CHANGING HAEMODIALYSIS POPULATION IN A SINGLE UK CENTRE: A POST PANDEMIC PHENOMENON?
Joanna McKinnell, United Kingdom

PSYCHOSOCIAL ASSESSMENTS AND HOSPITAL ADMISSION RATES IN ELEVATED OR HIGH ACUITY HEMODIALYSIS PATIENTS
Sheetal Chaudhuri, United States of America

ASSOCIATION OF PROLONGED QT INTERVALS WITH MORTALITY IN HEMODIALYSIS PATIENTS: A NATIONWIDE RETROSPECTIVE COHORT STUDY.
Sho Sasaki, Japan

THE LONG-TERM EFFECT OF A LUNG-ULTRASOUND INTERVENTION ON THE RISK FOR DEATH, HEART FAILURE AND MYOCARDIAL INFARCTION IN DIALYSIS PATIENTS.

Claudia Torino, Italy

HALL AMBER 3 & 4

17:00-18:15 (CEST)

Free Communication 7 THE ANCA VASCULITIS VARIETY SESSION

Chairs: Anne Mühlig & Ariela Benigni

Mini Lecture: Anne Mühlig, Germany (YPNN-ESPN)

THE CALCIUM-SENSING RECEPTOR STABILIZES PODOCYTE FUNCTION IN PROTEINURIC HUMANS AND MICE



♥ THE INVOLVEMENT OF NRF2-MEDIATED ANTIOXIDANT SYSTEM IN MYELOPEROXIDASE-POSITIVE ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Yusho Ueda, Japan

PROGNOSTIC FACTORS IN RENAL AND PATIENT SURVIVAL IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS
Hatice Sahin, Turkey

★ COMBINED ACTIVITY AND CHRONICITY SCORE FOR PROGNOSTIC ASSESSMENT IN ANCA-ASSOCIATED VASCULITIS WITH GLOMERULONEPHRITIS
Marta Casal Moura, United States of America

PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES
Jiahua Li, United States of America

17
SAT

SCIENTIFIC PROGRAMME

HALL AMBER 5

17:00-18:15 (CEST)

**CREATIVE LABS IV: BALANCING
PARENTHOOD AND CAREER**

Ana Carina Ferreira, Portugal

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023 5

FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42

**18
SUN**

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

DIABETES IN CKD: THE KDIGO GUIDELINE UPDATE	43
GETTING THE PATIENTS VOICE HEARD	43
CLINICAL ISSUES IN PERITONEAL DIALYSIS II	43
RECIPIENT EVALUATION	43
DR. HOUSE, COULD IT BE LUPUS?	44
AKI ALCHEMY	44
THE GOOD, THE BAD, AND THE CYSTIC	44
BLOODY STONES!	44
PLENARY LECTURE 3 - YOUNG AWARDEES	45
NEPHROLOGY PEARLS (CLOSING SESSION)	45

HALL GOLD (PLENARY)

08:30-09:45 (CEST)

Symposium 0.6 DIABETES IN CKD: THE KDIGO GUIDELINE UPDATE

Chairs: Mario Cozzolino & Michel Jadoul

1. Highlights from the 2022 Guideline Update on Diabetes in CKD; Implications of key publications (EMPA-KIDNEY, SMART-C, DELIVER, SURPASS)
Katherine Turtle, United States of America
2. ADA/KDIGO and ADA/EASD Consensus Reports
Peter Rossing, Denmark
3. Implementation of the KDIGO Diabetes Guideline for the European context
Frederik Persson, Denmark

HALL AUDITORIUM

08:30-09:45 (CEST)

Symposium 3.6 GETTING THE PATIENTS VOICE HEARD

Chairs: Daniel Gallego & Juan Carlos Julián

1. Clinical care: Outcomes that matter to CKD patients
Martin Wilkie, United Kingdom
2. Patient involvement in clinical studies
Wanda Konijn & Hanneke Vervoort, The Netherlands
3. Involving patients in guideline development
Tess Harris, United Kingdom

HALL SPACE 1 & 2

08:30-09:45 (CEST)

Symposium 4.3 CLINICAL ISSUES IN PERITONEAL DIALYSIS II

Chairs: Gianfranca Cabiddu & Angela Wang

1. Medical versus surgical intervention for advanced SHPT – which is better in dialysis patients?
Angela Wang, Hong Kong
2. Incremental PD – Should this be the standard start in all incident PD Patients?
Joanne Bargman, Canada
3. Promoting Exercise and physical activity in PD
Monika Lichodziejewska-Niemierko, Poland

HALL SPACE 3 & 4

08:30-09:45 (CEST)

Symposium 5.2 RECIPIENT EVALUATION

Chairs: Rachel Hellemans & Umberto Maggiore

1. How to tackle the obesity pandemic in transplant candidates: the Descartes guideline
Stephen O'Neill, United Kingdom
2. Retransplant candidates with failed graft: nephrectomy, management of immunosuppressants and other issues.
Luuk Hibbrands, The Netherlands
3. Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?
Charles Ferro, United Kingdom

HALL BROWN 3

08:30-09:45 (CEST)

Free Communication 5
DR. HOUSE, COULD IT BE LUPUS?**Chairs:** Gabriella Moroni & Manuel Praga**Mini Lecture:** Sydney CW Tang, Hong Kong
INNATE IMMUNITY IN DIABETIC KIDNEY DISEASE

♥ CLINICAL AND HISTOLOGICAL CHARACTERISTICS AND LONG-TERM PROGNOSIS OF LATE-ONSET LUPUS NEPHRITIS

Amir Shabaka, Spain

APOL1 GENOTYPE IS A MAJOR DETERMINANT OF LUPUS NEPHRITIS SEVERITY IN PATIENTS OF AFRICAN ANCESTRY

*Carole Burger, France*EFFICACY AND SAFETY OF VOCLOSPORIN IN PATIENTS WITH PROTEINURIA ≥ 2 MG/MG: AN INTEGRATED ANALYSIS OF THE AURA-LV AND AURORA 1 STUDIES
Salem Almaani, United States of America

★ B-CELL RECOVERY IN A RANDOMIZED CONTROLLED TRIAL OF B-CELL DEPLETION WITH OBINUTUZUMAB FOR THE TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS (NOBILITY)

Dario Roccatello, Italy

HALL BROWN 1 & 2

08:30-09:45 (CEST)

Free Communication 24
AKI ALCHEMY**Chairs:** Gulay Demirtas & Francesco Trepiccione**Mini Lecture:** Sho Hasegawa, Japan (JSN)
ACTIVATION OF SYMPATHETIC SIGNALING IN MACROPHAGES BLOCKS SYSTEMIC INFLAMMATION AND PROTECTS AGAINST RENAL ISCHEMIA-REPERFUSION INJURY

RECOMBINANT HIGH-DENSITY LIPOPROTEIN MODULATES INFLAMMATORY RESPONSE AND RENAL DYSFUNCTION IN A SWINE MODEL OF SEPSIS-INDUCED ACUTE KIDNEY INJURY

Alessandra Stasi, Italy

SHORT-CHAIN FATTY ACIDS, PROPIONATE AND BUTYRATE, RESEMBLE THE BENEFICIAL EFFECTS OF VITAMIN D DURING ACUTE KIDNEY DAMAGE.

*Viviana Corte-Iglesias, Spain*CYCLIN D1 AMELIORATES ACUTE KIDNEY INJURY BY IMPROVING FATTY ACID OXIDATION VIA AMPK PATHWAY
*Yuliang Huang, P.R. China*MICROPLASTICS: FIRST EXTENDED PROTEOMIC ANALYSIS ON KIDNEY TUBULAR CELLS
Carla Cervello, Italy

HALL AMBER 1 & 2

08:30-09:45 (CEST)

Free Communication 1
THE GOOD, THE BAD, AND THE CYSTIC**Chairs:** Roman-Ulrich Müller & Carsten Wagner**Mini Lecture:** Roser Torra
PKD: SCREENING FOR CEREBRAL ANEURYSMS?★ THE AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE PROTEIN, FPC, RELEASES MITOCHONDRIA LOCALISING FRAGMENTS INVOLVED IN PREVENTING CYSTOGENESIS
Rebecca Walker, United Kingdom

♥ DEVELOPMENT OF A NEW CELLULAR MODEL TO EVALUATE THE CLINICAL IMPACT OF PKD1 VARIANTS EXPLOITING CRISPR/CAS9 SYSTEM

Martina Migliorero, Italy

♥ RAPIDLY PROGRESSIVE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: RISK FACTORS FOR DISEASE SEVERITY DURING CHILDHOOD AND EARLY ADULTHOOD.

Stijn Wigerinck, Belgium♥ DIAGNOSTIC YIELD OF A TARGETED GENE PANEL FOR MONOGENIC KIDNEY DISEASES: AN EUROPEAN STUDY
Silvia Giovanella, Italy

HALL AMBER 3 & 4

08:30-09:45 (CEST)

Free Communication 12
BLOODY STONES!**Chairs:** Giovanni Gambaro & Markus Ketteler**Mini Lecture:** Giovanni Gambaro, Italy
WHAT'S NEW IN UROLITHIASIS EUROPEAN GUIDELINESEVALUATION OF HAEMOGLOBIN RESPONSE IN PATIENTS WITH CKD-RELATED ANAEMIA NOT ON DIALYSIS RECEIVING DAPRODUSTAT OR CONTROL IN ASCEND-ND
Vivekanand Jha, India♥ PROFILES OF HEMOGLOBIN TRAJECTORY IN CKD PATIENTS AND ASSOCIATED RISKS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS: THE CKD-REIN COHORT STUDY
*Lisa Le Gall, France*EFFECTS OF FERRIC CITRATE HYDRATE ON FIBROBLAST GROWTH FACTOR 23 AND PLATELET COUNT IN CKD AND NON-CKD PATIENTS WITH IRON DEFICIENCY ANAEMIA
*Kyoko Ito, Japan*DAPRODUSTAT VERSUS RECOMBINANT HUMAN ERYTHROPOIETIN FOR TREATING ANAEMIA OF CHRONIC KIDNEY DISEASE: COST EFFECTIVENESS MODEL METHODOLOGY AND FINDINGS
Alfred Sackeyfio, United Kingdom

18
SUN

SCIENTIFIC PROGRAMME

HALL GOLD (PLENARY)

10:00-10:45 (CEST)

PLENARY LECTURE 3 - YOUNG AWARDEES

Chairs: Ivan Rychlik & Alexander Rosenkranz

1. Basic Science
Christoph Kuppe, Germany
2. Translational Science
Stefanie Steiger, Germany
Edouard Fu, The Netherlands
3. Clinical Science
Olivier Aubert, France

HALL GOLD (PLENARY)

11:00-12:15 (CEST)

Symposium 0.5 NEPHROLOGY PEARLS (CLOSING SESSION)

Chairs: Christoph Wanner & Francesca Mallamaci

1. Basic Science and Translational Nephrology
Nicole Endlich, Germany
2. Epidemiology and Clinical Nephrology
Manuel Ferraro, Italy
3. ESKD and Dialysis
Christian Combe, France
4. Kidney Transplantation
Rachel Hellemans, Belgium

16
FRI

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

CONTENT &
DAILY INDEX

**INDUSTRY SPONSORED
SYMPOSIA**

FRIDAY - JUNE 16, 2023 46

SATURDAY - JUNE 17, 2023 56

KDIGO 2023 CKD GUIDELINE: A BRAVE NEW WORLD ON THE EVALUATION, PROGNOSTICATION, AND MANAGEMENT OF KIDNEY DISEASE	49
GENETIC SCREENING IN ADULT PATIENTS WITH END-STAGE KIDNEY DISEASE (ESKD)	49
C3G AND IC-MPGN: FROM UNMET NEEDS TO A COLLABORATIVE APPROACH TOWARDS IMPROVING OUTCOMES	49
IGA NEPHROPATHY: WHERE WE ARE NOW AND WHERE WE ARE GOING	49
THE WINDOW OF OPPORTUNITY IN LUPUS NEPHRITIS: WHEN TO ACT TO IMPROVE KIDNEY OUTCOMES?	51
FROM FIRST EVIDENCE TO FUTURE THERAPY: LEARNINGS FROM 2 DECADES OF FABRY EXPERIENCE	51
POTASSIUM CONTROL ACROSS THE SPECTRUM OF CKD – OPTIMISING RAASI THERAPY AND IMPROVING PATIENT OUTCOMES	51
BEYOND THE KIDNEY: NEW PERSPECTIVES IN INHERITED RARE DISEASES	53
GLP-1 RAS: TOWARDS AN UNMET NEED OF PEOPLE WITH T2D AND CKD	53
INSPIRED TO MOVE MOUNTAINS: EMERGING THERAPIES IN LUPUS NEPHRITIS	53
ANCA-ASSOCIATED VASCULITIS, THE KIDNEY AND BEYOND	53
ANEMIA OF CKD: TIME TO TAKE ACTION	54

CONTENT & DAILY INDEX

INDUSTRY SPONSORED SYMPOSIA

FRIDAY - JUNE 16, 2023 46

SATURDAY - JUNE 17, 2023 56

16
FRI

DAY AT A
GLANCE

60TH ERA
CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

EXPLORE THE LATEST HOT TOPIC WITHIN IV IRON IN CKD AND HEART FAILURE	54
WHAT'S NEW IN THE MANAGEMENT OF ATYPICAL HEMOLYTIC URAEMIC SYNDROME?	54
ADSORPTION IN CHRONIC AND ACUTE CLINICAL SETTINGS	55
LUPUS NEPHRITIS: CURRENT CHALLENGES AND NOVEL TREATMENT STRATEGIES	55

The Boehringer Ingelheim and Lilly Alliance is committed to helping people with Cardiovascular, Renal and Metabolic conditions

Investment in research
Educational resources
REDUCE RISK OF DISEASE PROGRESSION
OVERCOME CLINICAL INERTIA
Manage comorbidities
MULTICHANNEL COMMUNICATION
**AWARENESS
IN PRIMARY CARE**
Guideline implementation RCTs
EARLY INTERVENTION
OPTIMISING PATIENT CARE

SPACE 1 & 2

10:00 - 11:00 (CEST)

**ISS 1.1
KDIGO 2023 CKD GUIDELINE:
A BRAVE NEW WORLD
ON THE EVALUATION,
PROGNOSTICATION, AND
MANAGEMENT OF KIDNEY
DISEASE**

Chair: Adeera LEVIN, Canada

1. Welcome & Introductions
Adeera LEVIN, Canada
2. KDIGO 2023 CKD GL: Vision for the guideline: Why now?
Paul STEVENS, United Kingdom
3. KDIGO 2023 CKD GL: Evaluation of CKD: What's changed?
Rumeyza KAZANCIOLU, Turkey
4. KDIGO 2023 CKD GL: Delaying CKD Progression and Complications: What's new?
Magdalena MADERO, Mexico
5. Q&A
Adeera LEVIN, Canada

ORGANIZED BY



SPACE 3 & 4

10:00 - 11:00 (CEST)

**ISS 1.2
GENETIC SCREENING IN ADULT
PATIENTS WITH END-STAGE
KIDNEY DISEASE (ESKD)**

Chair: Pietro Manuel FERRARO, Italy

1. Welcome and introductions
Pietro Manuel FERRARO, Italy
2. Clinical utility of genetic testing in adults patients with CKD and ESKD
Nine KNOERS, The Netherlands
3. Overcoming the challenges and barriers to genetic screening in routine clinical practice
Carsten BERGMANN, Germany
4. How to successfully implement a screening programme for a rare genetic condition
Pietro Manuel FERRARO, Italy
5. Panel discussion and summary
All faculty

ORGANIZED BY



BROWN 3

10:00 - 11:00 (CEST)

**ISS 1.3
C3G AND IC-MPGN:
FROM UNMET NEEDS TO A
COLLABORATIVE APPROACH
TOWARDS IMPROVING
OUTCOMES**

Chair: Fadi FAKHOURI, Switzerland

1. Welcome and introduction
Fadi FAKHOURI, Switzerland
2. Current state of evidence in C3G and IC-MPGN and impact of uncertainties on clinical management
Fadi FAKHOURI, Switzerland
3. The CompCure Association - on a mission to address evidence gaps
Marianne SILKJAER-NIELSEN, Switzerland
4. A comprehensive European Registry for C3G and IC-MPGN
Franz SCHAEFER, Germany
5. Audience Q&A
All faculty
6. Closing remarks
Fadi FAKHOURI, Switzerland

ORGANIZED BY



BROWN 1 & 2

10:00 - 11:00 (CEST)

**ISS 1.4
IGA NEPHROPATHY: WHERE WE
ARE NOW AND WHERE WE ARE
GOING**

Chair: Dana RIZK, United States of America

1. Complexity of IgAN management from a clinician perspective
Rosanna COPPO, Italy
2. Review the emerging treatment landscape in IgAN
Dana RIZK, United States of America

ORGANIZED BY



Did you know . . .

Blockade of the ETA receptor with potent and selective ETA antagonism represents a potential approach to treat IgAN patients at high risk of progression.



Changing the Course
of Kidney Care™



www.chinooktx.com



AMBER 1 & 2

10:00 - 11:00 (CEST)

ISS 1.5
THE WINDOW OF OPPORTUNITY
IN LUPUS NEPHRITIS: WHEN
TO ACT TO IMPROVE KIDNEY
OUTCOMES?

Chair: Liz LIGHTSTONE, United Kingdom

1. Welcome and Introduction
Liz LIGHTSTONE, United Kingdom
2. Case study 1: Forward thinking in the management of lupus nephritis
Lucio MANENTI, Italy
3. Case Study Discussion
Liz LIGHTSTONE, United Kingdom
4. Case study 2: Can we meet the challenge to improve kidney outcomes in lupus nephritis?
Y.K. Onno TENG, The Netherlands
5. Case study discussion
Liz LIGHTSTONE, United Kingdom
6. Closing Remarks
All faculty

ORGANIZED BY



AMBER 3 & 4

10:00 - 11:00 (CEST)

ISS 1.6
FROM FIRST EVIDENCE TO
FUTURE THERAPY: LEARNINGS
FROM 2 DECADES OF FABRY
EXPERIENCE

Chair: Antonio PISANI, Italy

1. Introduction
Antonio PISANI, Italy
2. More than 20 years of the patient-centered Fabry Registry: Real-world scientific evidence advancing Fabry disease expertise and better informing the Fabry community
Alberto ORTIZ, Spain
3. Cleared podocytes and normal kidney function in classical Fabry males 15 years after start of enzyme replacement therapy at young age
Camilla TØNDEL, Norway
4. Future oral therapies focusing on glucosylceramide synthase inhibition: evidence from clinical programs
Patrick DEEGAN, United Kingdom
5. Q & A
All faculty

ORGANIZED BY



AMBER 5

10:00 - 11:00 (CEST)

ISS 1.7
POTASSIUM CONTROL ACROSS
THE SPECTRUM OF CKD –
OPTIMISING RAASI THERAPY
AND IMPROVING PATIENT
OUTCOMES

Chair: Francesca MALLAMACI, Italy

1. Hyperkalaemia – still an issue in the management of CKD?
Maria C. HALLER, Austria
2. Potassium control across the spectrum of CKD – practical guidance and novel therapeutic options
Patrick ROSSIGNOL, France
3. Optimising RAAS inhibition in patients with CKD and comorbidities – current guidelines and lessons from recent trials
Charles J. FERRO, United Kingdom
4. Interactive panel discussion
All faculty

ORGANIZED BY



RAASi therapy is vital for patients with CKD and/or heart failure, but hyperkalemia can limit its use¹⁻³

Want to hear more? This KDIGO podcast features a discussion on the benefits of RAASi utilisation

LISTEN TODAY



KDIGO Conversations in Nephrology



LISTEN TO THE PODCAST



CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; RAASi, renin-angiotensin-aldosterone system inhibitor.

1. Epstein M, et al. *Am J Manag Care* 2015;21(11 Suppl):S212-S220. 2. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int* 2021;99(3S):S1-S87. 3. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42(36):3599-3726.

Q-NA-2300034 | Date of preparation: March 2023

CSL Vifor

SPACE 1 & 2

13:30 - 14:30 (CEST)

**ISS 1.8
BEYOND THE KIDNEY: NEW
PERSPECTIVES IN INHERITED
RARE DISEASES****Chair:** *Christoph WANNER, Germany*

1. Welcome and introduction
Christoph WANNER, Germany
2. The importance of patients' perspective for the assessment of symptoms. The unmet needs in FD from a patients' perspective. Results of the patients' survey
Roser TORRA, Spain
3. The importance of patients' perspective for the assessment of symptoms. Adults' patients' management in NC: clinical case reports
Aude SERVAIS, France
4. How to update the optimal monitoring in FD considering the new data
Antonio PISANI, Italy
5. Closing and remarks
Christoph WANNER, Germany

ORGANIZED BY



SPACE 3 & 4

13:30 - 14:30 (CEST)

**ISS 1.9
GLP-1 RAS: TOWARDS AN
UNMET NEED OF PEOPLE WITH
T2D AND CKD****Chair:** *Peter ROSSING, Denmark*

1. Welcome and Introduction
Peter ROSSING, Denmark
2. What are we looking for in treatment of people with CKD and T2D?
Adeera LEVIN, Canada
3. Clinical and treatment landscape of CKD and T2D.
Roland E. SCHMIEDER, Germany
4. FLOW trial population: What FLOW GLP-1 RA kidney outcomes trial will add to current knowledge?
Hiddo LAMBERS HEERSPINK, The Netherlands

ORGANIZED BY



BROWN 3

13:30 - 14:30 (CEST)

**ISS 1.10
INSPIRED TO MOVE MOUNTAINS:
EMERGING THERAPIES IN LUPUS
NEPHRITIS****Chair:** *Gabriella Luisa MORONI, Italy*

1. Welcome and introduction
Gabriella Luisa MORONI, Italy
2. Reaching base camp: B-cell depletion
Rachel JONES, United Kingdom
3. One step at a time: complement inhibition
Marina VIVARELLI, Italy
4. Climbing to the peak: from theory to clinical reality
Liz LIGHTSTONE, United Kingdom
5. Q&A and close
Gabriella Luisa MORONI, Italy

ORGANIZED BY



BROWN 1 & 2

13:30 - 14:30 (CEST)

**ISS 1.11
ANCA-ASSOCIATED VASCULITIS,
THE KIDNEY AND BEYOND****Chair:** *Andreas KRONBICHLER, Austria*

1. Welcome and introduction
Andreas KRONBICHLER, Austria
2. Targeting unmet needs in clinical practice
Federico ALBERICI, Italy
3. Ongoing challenges in ANCA-associated vasculitis – can we do better?
Silke BRIX, United Kingdom
4. Q&A and Concluding Remarks
Andreas KRONBICHLER, Austria

ORGANIZED BY

CSL Vifor

AMBER 1 & 2

13:30 - 14:30 (CEST)

ISS 1.12
ANEMIA OF CKD: TIME TO TAKE ACTION**Chair:** Lucia DEL VECCHIO, Italy

1. Welcome and introduction
Lucia DEL VECCHIO, Italy
2. Anemia of CKD: common, yet under-recognised?
Ciro ESPOSITO, Italy
3. Patient-centred care to optimise current treatment
Ciro ESPOSITO, Italy
Frank STRUTZ, Germany
4. Latest innovations in patient care
Frank STRUTZ, Germany
5. Summary and close
Lucia DEL VECCHIO, Italy

ORGANIZED BY

GSK

AMBER 3 & 4

13:30 - 14:30 (CEST)

ISS 1.13
EXPLORE THE LATEST HOT TOPIC WITHIN IV IRON IN CKD AND HEART FAILURE**Chair:** Loreto GESUALDO, Italy

1. The value of an anemia management in a cardiorenal clinic
Philip A. KALRA, United Kingdom
2. IRONMAN Trial Design – The emerging role of IV iron to reduce cardiovascular risk, particularly risk of hospitalisation for heart failure
Fozia AHMED, United Kingdoms

ORGANIZED BY

PHARMACOSMOS

AMBER 5

13:30 - 14:30 (CEST)

ISS 1.14
WHAT'S NEW IN THE MANAGEMENT OF ATYPICAL HEMOLYTIC URAEMIC SYNDROME?**Chair:** Manuel PRAGA, Spain

1. Overview of management approaches to aHUS
Manuel PRAGA, Spain
2. Clinical and real-world experience with currently available targeted treatments for aHUS
Anuja JAVA, United States of America
3. Recognition and management of aHUS in the presence of associated clinical conditions and events
Sjoerd TIMMERMANS, The Netherlands
4. Q&A session
All faculty

ORGANIZED BY

ALEXION
AstraZeneca Rare Disease

AMBER 1 & 2

18:30 - 19:30 (CEST)

ISS 1.15
ADSORPTION IN CHRONIC AND ACUTE CLINICAL SETTINGS

Chairs: *Claudio RONCO, Italy & Thomas Rimmelé, France*

1. Opening & Introduction
Claudio RONCO, Italy
2. Improving Uremic Complications: How can Hemoadsorption Help
Dr.Vincenzo Cantaluppi, Italy
3. Hemoadsorption in Septic Patients: Clinical Experience
Thomas RIMMELÉ, France
4. DPMAS in ACLF. The PADSTONE study on 1300 Patients
Jinjun CHEN, China
5. Discussion
All faculty

ORGANIZED BY



AMBER 3 & 4

18:30 - 19:30 (CEST)

ISS 1.16
LUPUS NEPHRITIS: CURRENT CHALLENGES AND NOVEL TREATMENT STRATEGIES

Chair: *Y.K.Onno TENG, The Netherlands*

1. Introduction
Y.K.Onno TENG, The Netherlands
2. Current treatment: what are the unmet needs?
Andrea Doria, Italy
3. New therapeutic options: is a paradigm change possible?
Gabriella Luisa MORONI, Italy
4. Interactive survey and live Q&A
All faculty

ORGANIZED BY



CONTENT & DAILY INDEX

INDUSTRY SPONSORED SYMPOSIA

FRIDAY - JUNE 16, 2023 46

SATURDAY - JUNE 17, 2023 56


**17
SAT**

DAY AT A
GLANCE

**60TH ERA
CONGRESS
MILAN & VIRTUAL**
JUNE 15-18, 2023

CHALLENGES AND OPPORTUNITIES IN IGA NEPHROPATHY: TARGETING THE ALTERNATIVE COMPLEMENT PATHWAY	58
STRENGTHENING EXPERTISE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE	58
CONTINUING LIFESAVING THERAPY IN THE CARDIORENAL PATIENT: PRACTICAL GUIDANCE FOR MANAGING HYPERKALEMIA	58
THROUGH DIFFERENT LENSES: UNDERSTANDING THE COMPLEXITY OF C3G AND IC-MPGN	58
FILLING THE GAP BY TARGETING THE GUT - FIRST DISEASE MODIFYING TREATMENT APPROVED FOR IGAN	59
THERAPEUTIC APHERESIS: FUTURE CHALLENGES	59
PATIENT-CENTRED CARE IN DIALYSIS: LET'S TACKLE CKD-ASSOCIATED PRURITUS	59
ACHIEVING SUCCESS IN IGAN & FSGS: EXPERT INSIGHTS ON CURRENT AND FUTURE THERAPIES	60
RESHAPING KIDNEY CARE – ESTABLISHING THE FULL POTENTIAL OF SGLT2 INHIBITORS AS STANDARD-OF-CARE	60
IMMUNO-NEPHROLOGY: THE DIALYSIS MEMBRANE AS A THERAPEUTIC STRATEGY	60
HEMOCOMPATIBILITY OF DIALYZERS – HOW NOVEL MEMBRANES MAY IMPROVE HEMODIALYSIS TREATMENT	60
NONSTEROIDAL MRAS: A NEW PILLAR OF TREATMENT FOR CARDIORENAL PROTECTION IN CKD AND T2D	62
COMPLEX PATHOPHYSIOLOGY AND MANAGEMENT IN ANAEMIA OF CKD: IS ROXADUSTAT THE ANSWER?	62
ENSURING A TREATMENT CONTINUUM FOR CKD-MBD	62

In Pursuit of Possibilities in IgA Nephropathy



SPACE 1 & 2

10:00 - 11:00 (CEST)

ISS 2.1 CHALLENGES AND OPPORTUNITIES IN IGA NEPHROPATHY: TARGETING THE ALTERNATIVE COMPLEMENT PATHWAY

Chairs: Jürgen FLOEGE, Germany & Richard LAFAYETTE, United States of America

1. Welcome and introduction
Richard LAFAYETTE, United States of America
2. The challenges with IgAN in clinical practice today
Smeeta SINHA, United Kingdom
3. Complement in IgAN: A key driver of the pathogenesis?
Sydney TANG, Hong Kong, P.R. China
4. Audience Q&A
All faculty
5. Closing remarks
All faculty

ORGANIZED BY

 **NOVARTIS** | Reimagining Medicine

SPACE 3 & 4

10:00 - 11:00 (CEST)

ISS 2.2 STRENGTHENING EXPERTISE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE

Chair: Jolanta MAŁYSZKO, Poland

1. Welcome & Introduction
Jolanta MAŁYSZKO, Poland
2. Challenges and opportunities in the treatment in CKD
David C. WHEELER, United Kingdom
3. Improving clinical outcomes in CKD: novel approaches
Roberto PONTREMOLI, Italy
4. Commentary: Practical considerations for CKD management
Rikke BORG, Denmark
5. Discussion & Closure
Jolanta MAŁYSZKO, Poland

ORGANIZED BY



BROWN 3

10:00 - 11:00 (CEST)

ISS 2.3 CONTINUING LIFESAVING THERAPY IN THE CARDIORENAL PATIENT: PRACTICAL GUIDANCE FOR MANAGING HYPERKALEMIA

Chair: James BURTON, United Kingdom

1. Welcome and introductions
James BURTON, United Kingdom
2. Catch-22 – hyperkalemia and RAASi
Manish SOOD, Canada
3. Reaching consensus – Optimising care for cardiorenal patients Panel Discussion
Shelley ZIEROTH, Canada
4. Q&A
All faculty

ORGANIZED BY



BROWN 1 & 2

10:00 - 11:00 (CEST)

ISS 2.4 THROUGH DIFFERENT LENSES: UNDERSTANDING THE COMPLEXITY OF C3G AND IC-MPGN

Chair: Fernando CARAVACA-FONTÁN, Spain

1. Chair's welcome
Fernando CARAVACA-FONTÁN, Spain
2. Beneath the surface: the heterogeneous pathophysiology of C3G/IC-MPGN
Marina NORIS, Italy
3. Demystifying the diagnostic pathway and disease progression in C3G/IC-MPGN
Fernando CARAVACA-FONTÁN, Spain
4. The patient voice: the uncertainty of living with severe progressive kidney disease
Antonia KING, Germany
5. Closing remarks and Q&A: Can we redefine the future of patient management in C3G/IC-MPGN
Fernando CARAVACA-FONTÁN, Spain

ORGANIZED BY



AMBER 1 & 2

10:00 - 11:00 (CEST)

ISS 2.5
FILLING THE GAP BY TARGETING THE GUT - FIRST DISEASE MODIFYING TREATMENT APPROVED FOR IGAN

Chair: *Francesco Paolo SCHENA, Italy*

1. Welcome and Introduction
Francesco Paolo SCHENA, Italy
2. Nefecon – Rationale, Efficacy and Safety in the Treatment of Primary IgA Nephropathy
Bengt FELLSTRÖM, Sweden
3. Nefigard and Beyond – Treating IgA Nephropathy in 2023
Jonathan BARRATT, United Kingdom
4. Discussion & Closing Remarks
Bengt FELLSTRÖM, Sweden, Jonathan BARRATT, United Kingdom

ORGANIZED BY



Caring for People's Health

AMBER 3 & 4

10:00 - 11:00 (CEST)

ISS 2.6
THERAPEUTIC APHERESIS: FUTURE CHALLENGES

Chair: *Emanuela DE PASCALE, Italy*

1. An apheresis centre – novel interdisciplinary treatment opportunities for nephrologists
Benjamin SAVENKOFF, France
2. Lipoprotein apheresis - Quo vadis ?
Reinhard Georg KLINGEL, Germany
3. Post-COVID-19 syndrome - is there a role for apheresis?
Bernd HOHENSTEIN, Germany
4. Q&A
All faculty

ORGANIZED BY

AMBER 5

10:00 - 11:00 (CEST)

ISS 2.7
PATIENT-CENTRED CARE IN DIALYSIS: LET'S TACKLE CKD-ASSOCIATED PRURITUS

Chair: *Lucio MANENTI, Italy*

1. Welcome and introduction
Lucio MANENTI, Italy
2. An insight into the burden and prevalence of CKD-associated Pruritus
Antoine LANOT, France
3. An opportunity to improve CKD-associated Pruritus: Sharing clinical experience of difelikefalin
Leonie KRAFT, Germany
4. An opportunity to improve CKD-associated Pruritus: Sharing clinical experience of difelikefalin
Jörg LATUS, Germany
5. A changing landscape for the treatment of CKD-associated Pruritus
Lucio MANENTI, Italy
6. Q&A
All faculty
7. Summary and meeting close
All faculty

ORGANIZED BY

SPACE 1 & 2

13:30 - 14:30 (CEST)

ISS 2.8 ACHIEVING SUCCESS IN IGAN & FSGS: EXPERT INSIGHTS ON CURRENT AND FUTURE THERAPIES

Chair: Sian GRIFFIN, United Kingdom

1. Welcome
Sian GRIFFIN, United Kingdom
2. IgA Nephropathy Patient Case 1
Jürgen FLOEGE, Germany
3. IgA Nephropathy Patient Case 2
Loreto GESUALDO, Italy
4. IgAN Panel Discussion
All faculty
5. FSGS Patient Case
Sian GRIFFIN, United Kingdom
6. Panel Discussion, Take-Home Messages,
and Question and Answer Session
All faculty

ORGANIZED BY



SPACE 3 & 4

13:30 - 14:30 (CEST)

ISS 2.9 RESHAPING KIDNEY CARE – ESTABLISHING THE FULL POTENTIAL OF SGLT2 INHIBITORS AS STANDARD-OF- CARE

Chair: Kieran MCCAFFERTY, United Kingdom

1. Welcome and introductions
Kieran MCCAFFERTY, United Kingdom
2. From early to late in CKD – Nephrologists
and their role before secondary care
Kieran MCCAFFERTY, United Kingdom
3. Time to make flozination as standard-of-
care
David CHERNEY, Canada
4. Overcoming barriers to the use of SGLT2
inhibitors – Learnings from our journey
so far
Paola FIORETTO, Italy
5. Panel discussion and Q&A
All faculty
6. Closing remarks
Kieran MCCAFFERTY, United Kingdom

ORGANIZED BY

SCIENCE COLLECTED

BROWN 3

13:30 - 14:30 (CEST)

ISS 2.10 IMMUNO-NEPHROLOGY: THE DIALYSIS MEMBRANE AS A THERAPEUTIC STRATEGY

Chairs: Ikuto MASAKANE, Japan &
Giuseppe CASTELLANO, Italy

1. Waiting transplant patient and DGF: role of
PMMA membrane
Giuseppe CASTELLANO, Italy
2. New frontier of anti-thrombogenic
membrane: technology and clinical
applications
Philippe RIEU, France
3. Inhibiting Complement Activation in Septic-
AKI: Why Considering PMMA-based
dialysis
Vincenzo CANTALUPPI, Italy
4. Final discussion
All faculty

ORGANIZED BY



BROWN 1 & 2

13:30 - 14:30 (CEST)

ISS 2.11 HEMOCOMPATIBILITY OF DIALYZERS – HOW NOVEL MEMBRANES MAY IMPROVE HEMODIALYSIS TREATMENT

Chair: Alberto ORTIZ, Spain

1. Welcome and Introduction
Alberto ORTIZ, Spain
2. Inflammation – the fire that burns within
Peter STENVINKEL, Sweden
3. Biocompatibility of dialyzer membranes:
relevance in current clinical practice
Muriel GROOTEMAN, The Netherlands
4. From bench to bedside – the new helixone
hydro membrane
Fatih KIRCELLI, Germany
5. Q&A
All faculty

ORGANIZED BY



Complex pathophysiology and management in anaemia of CKD: is roxadustat the answer?

📅 Saturday 17 June 2023 ⌚ 13:30–14:30 CEST 📍 Amber 3 & 4, Level +2, MiCo

Faculty:



Chairperson:
Professor
Mario Cozzolino,
University of Milan,
Italy



Professor
Denis Fouque,
University Claude
Bernard, Lyon, France



Professor
Roberto Minutolo,
University of Campania,
Naples, Italy



Dr Monica Gross,
DaVita Falkensee,
Germany

Time	Session	Speaker
13:30–13:35	Welcome and introductions	Professor Mario Cozzolino
13:35–13:45	The complexities of anaemia of CKD: disease burden, pathophysiology and management	Professor Denis Fouque
13:45–14:10	Roxadustat and the impact of a physiological approach to treatment	Professor Roberto Minutolo
14:10–14:25	Roxadustat in the real-world: the patient experience	Dr Monica Gross
14:25–14:30	Q&A and meeting close	All

“ The symptoms of anaemia can be debilitating for our patients and effective management is key to improving quality of life and reducing the risk of adverse outcomes of anaemia in this challenging population.

This educational symposium will draw on the experience of the faculty to explore the clinical evidence, real-world experience, practicalities and potential of roxadustat, the first HIF-prolyl hydroxylase inhibitor to be approved for the treatment of adult patients with anaemia of CKD. ”

Professor Mario Cozzolino

CKD, chronic kidney disease; HIF, hypoxia-inducible factor.

This symposium has been sponsored by Astellas Pharma and is intended for healthcare professionals only. This symposium contains information about Astellas products.

AMBER 1 & 2

13:30 - 14:30 (CEST)

ISS 2.12
NONSTEROIDAL MRAS: A NEW PILLAR OF TREATMENT FOR CARDIORENAL PROTECTION IN CKD AND T2D

Chair: Giuseppe GRANDALIANO, Italy

1. Welcome and introduction
Giuseppe GRANDALIANO, Italy
2. Nonsteroidal MRAs as part of the comprehensive approach to CKD: Guideline updates
Beatriz FERNANDEZ-FERNANDEZ, Spain
3. Pillar approach for the treatment of CKD in T2D: Treat early to help prevent further CV and renal damage
Christoph WANNER, Germany
4. Beyond CKD progression: Cardiorenal protection across the spectrum of CKD in patients with T2D
Rajiv AGARWAL, United States of America
5. Q&A
All faculty
6. Summary and close
Giuseppe GRANDALIANO, Italy

ORGANIZED BY



AMBER 3 & 4

13:30 - 14:30 (CEST)

ISS 2.13
COMPLEX PATHOPHYSIOLOGY AND MANAGEMENT IN ANAEMIA OF CKD: IS ROXADUSTAT THE ANSWER?

Chair: Mario Gennaro COZZOLINO, Italy

1. Welcome and introductions
Mario Gennaro COZZOLINO, Italy
2. The complexities of anaemia of CKD: disease burden, pathophysiology and management
Denis FOUQUE, France
3. Roxadustat and the impact of a physiological approach to treatment
Roberto MINUTOLO, Italy
4. Roxadustat in the real-world: the patient experience
Monica, Gross, Germany
5. Q&A and meeting close
Mario Gennaro COZZOLINO, Italy

ORGANIZED BY



AMBER 5

13:30 - 14:30 (CEST)

ISS 2.14
ENSURING A TREATMENT CONTINUUM FOR CKD-MBD

Chair: Smeeta SINHA, United Kingdom

1. Welcome and introduction to vascular calcification
Smeeta SINHA, United Kingdom
2. Importance of early and effective treatment of SHPT in non-dialysis CKD patients
Jan T. KIELSTEIN, Germany
3. Decreasing pill burden in dialysis patients: advances in hyperphosphataemia treatment
Maria Jesús LLORET, Spain
4. Key takeaways from the panel and close
All faculty

ORGANIZED BY

CSL Vifor



**See you next year
in Stockholm**



Save the date Vienna 2025



**62nd ERA
CONGRESS**
VIENNA & VIRTUAL
JUNE 4-7, 2025